Evolution of Exenatide as a Diabetes Therapeutic

Sunil Bhavsar,1,* Sunder Mudaliar2, * and Alan Cherrington3,*

1Amylin Pharmaceuticals, Inc., San Diego CA; 2VA San Diego Healthcare System and University of California at San Diego, San Diego CA; 3Vanderbilt University, Nashville TN, USA

Abstract: Type 2 diabetes (T2DM) is a disease of epidemic proportion associated with significant morbidity and excess mortality. Optimal glycemic control reduces the risk of microvascular and possibly macrovascular complications due to diabetes. However, glycemic control is rarely optimal and several therapeutic interventions for the treatment of diabetes cause hypoglycemia and weight gain; some may exacerbate cardiovascular risk. Exenatide (synthetic exendin-4) is a glucagon-like peptide-1 receptor (GLP-1R) agonist developed as a first-in-class diabetes therapy. This review presents an overview of the evolution of exenatide as a T2DM treatment, beginning with the seminal preclinical discoveries and continuing through to clinical pharmacology investigations and phase 3 clinical trials. In patients with T2DM, exenatide enhanced glucose-dependent insulin secretion, suppressed inappropriately elevated glucagon secretion, slowed gastric emptying, and enhanced satiety. In controlled phase 3 clinical trials ranging from 12 to 52 weeks, 10-mcg exenatide twice daily (ExBID) reduced mean HbA1c by -0.8% to -1.7% as monotherapy or in combination with metformin (MET), sulfonylureas (SFU), and/or thiazolidinediones (TZD); with mean weight losses of -1.2 kg to -8.0 kg. In controlled phase 3 trials ranging from 24 to 30 weeks, a 2-mg once-weekly exenatide formulation (ExQW) reduced mean HbA1c by -1.3% to -1.9%, with mean weight reductions of -2.3 to -3.7 kg. Exenatide was generally well-tolerated. The most common side effects were gastrointestinal in nature, mild, and transient. Nausea was the most prevalent adverse event. The incidence of hypoglycemia was generally low. By building upon early observations exenatide was successfully developed into an effective diabetes therapy.

Keywords: Diabetes mellitus, Exenatide, Exendin-4, GLP-1 receptor agonist.

INTRODUCTION

Diabetes is a disease of epidemic proportion [1,2], but glycemic control is rarely optimized and some therapeutic interventions cause hypoglycemia, weight gain and possibly exacerbate cardiovascular (CVD) risk [3]. Data from large studies indicate that restoration of glycemic control when coupled with weight loss can improve hypertension, dyslipidemia, and other CVD risk markers [4-6].

Exenatide (synthetic exendin-4) is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been developed as a first-in-class diabetes therapy. This review presents an overview of the evolution of exenatide as a treatment for type 2 diabetes (T2DM) from seminal preclinical discoveries, clinical pharmacology investigations, and phase 3 clinical trials (Fig. 1). By building upon early observations of anti-hyperglycemic actions by GLP-1 and Gila monster exendin-4, exenatide was successfully developed into a diabetes therapeutic agent with a broad range of beneficial cardiometabolic effects and an acceptable tolerability profile. A twice daily (BID) exenatide formulation is currently approved for use in patients with T2DM in the U.S., E.U., Japan, and other countries. A once weekly (QW) exenatide formulation is also currently approved for use in the U.S., E.U., and Japan, while a once-monthly formulation is undergoing clinical testing.

INCRETINS

The 'incretin effect' (Fig. 2A) was originally described as the observation that oral glucose stimulates insulin secretion to a greater extent than an intravenous infusion of glucose [7-11]. Later, ingestion of various solid foods was also found to stimulate this physiological response to nutrient ingestion. GLP-1 and glucose-dependent insulinotrophic polypeptide (ie, gastric inhibitory polypeptide [GIP]) are the gut hormones primarily responsible for the incretin effect. In healthy, normoglycemic adults the contributions of GLP-1 and GIP to the insulin secretory response to elevated circulating glucose concentrations (nutrient ingestion) are estimated to be 73% of the total response. Because of its pleiotropic metabolic effects and for the reasons explained below, GLP-1 quickly became the primary focus of drug development efforts for treating diabetes (Fig. 2B).

The GLP-1 Receptor and GLP-1

The GLP-1 receptor (GLP-1R) is a seven-transmembrane domain, G-protein coupled receptor expressed in pancreatic endocrine- and β-cells, kidney, heart and blood vessels, stomach, small and large intestine, lung, and brain [12-16]. The physiology of the GLP-1R and its ligand have been extensively explored within the context of glucose homeostasis
using GLP-1R(-/-) knockout (KO) mice [17-24]. GLP-1R KO mice have elevated blood glucose concentrations following an oral glucose challenge, coupled with lower than normal plasma insulin concentrations [17,19,20]. GLP-1 fails to stimulate insulin release from isolated pancreatic islets from GLP-1R KO mice, in sharp contrast to the 2-fold insulin stimulation in islets from normal mice and despite equivalent insulin content in islets from both mouse strains [18]. Similar results were observed using perfused pancreata [19]. In addition, De León et al. [24] examined β-cell mass regeneration after GLP-1R KO mice were 70% pancreatectomized. Five weeks post-surgery, β-cell mass was not significantly different between wild-type pancreatectomized or sham-operated mice. However, in GLP-1R KO mice, β-cell mass remained significantly lower in pancreatectomized versus sham-operated animals, confirming a role for GLP-1 in pancreatic islet regeneration in the mouse.

GLP-1, the only endogenous ligand for the GLP-1R, is rapidly secreted by the L-cells of the intestinal mucosa in response to nutrient ingestion [25]. This peptide hormone enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, slows gastric emptying, and reduces food intake [25-31]. In rodent models, GLP-1 treatment is associated with pancreatic islet neogenesis, β-cell proliferation, and increased β-cell mass [32-34].

Initially, a role for GLP-1 in ameliorating diabetes pathophysiology was explored using continuous infusion techniques to increase circulating GLP-1 concentrations [35]. In patients with T2DM, 6 weeks of continuous GLP-1 infusion significantly reduced HbA1c, fasting glucose, and post-prandial glucose excursions compared with placebo (PBO) infusion (Fig. 3). GLP-1 infusion also improved β-cell sensitivity to ambient glucose by 77% compared with baseline, and re-established a more normal pattern of both first- and second-phase insulin secretion. Gastric emptying was slowed and patients lost weight. GLP-1 reduced sensations of hunger, i.e., enhanced satiety and fullness, and reduced prospective food intake; these effects were absent with PBO infusion. In another study, intravenous infusion of GLP-1 prior to, and during, a glucose challenge in patients with T2DM was associated with an insulinotropic effect on both first- and second-phase insulin secretion, augmentation of glucose disappearance rates, and suppression of circulating glucagon levels [36]. Despite these positive effects, GLP-1 augmentation as a strategy to treat diabetes was deemed impractical, because GLP-1 is rapidly degraded in the circulatory system, by the enzyme dipeptidyl peptidase-IV (DPP-4), with a half-life of less than 2 minutes [37, 38].

**EXENDIN-4**

Exendin-4, the naturally occurring form of exenatide, was investigated as a potential ligand for the GLP-1R and a possible diabetes therapy after a number of nonclinical discoveries. Exendin-4 was originally isolated from the salivary secretions of the lizard *Heloderma suspectum* (Gila monster) [39,40]. Exendin-4 has a 53% amino acid sequence homology with mammalian GLP-1 Fig. (4) [39,40]. However, mammalian GLP-1 is processed from the proglucagon gene in L-cells in the small intestine, whereas lizard exendin-4 is transcribed from a different gene, not the Gila monster homologue of the mammalian proglucagon [41]. The second seminal discovery was that exendin-4 is resistant to degradation by DPP-4, the enzyme responsible for rapidly degrading endogenous GLP-1 [37,38]. Third, although exendin-4 is not an analogue of GLP-1, exendin-4 and GLP-1 share many glucoregulatory actions mediated by the GLP-1 receptor [42]. The pancreatic GLP-1 receptor binds exendin-4 and GLP-1 with equal affinity in *vivo*, and both peptides stimulate the receptor equipotently [42-45]. Hence, exendin-4 is a GLP-1R agonist.

Actions shared by exendin-4 and GLP-1 in non-human studies include reduction of hyperglycemia, glucose-dependent enhancement of insulin secretion, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake, often with body weight reduction or blunting of weight gain [39,44,46-49]. In both *in vitro* and *in vivo* preclinical models, exendin-4 promoted β-cell proliferation and islet neogenesis from precursor cells [33,50-56]. Further, as
a result of its enhanced pharmacokinetics compared to GLP-1, exendin-4 demonstrated very high in vivo potency relative to native GLP-1 [44,46,56].

Exendin-4 and Insulin-Secreting β-cells in Animal Models of Diabetes

The actions of exendin-4 on insulin secretion from pancreatic β-cell has been studied in a number of animal models of T2DM. T2DM is characterized by progressive loss of β-cell function [3,4,5,58,59]. The emergence of overt T2DM is precipitated by the failure of pancreatic β-cells to secrete adequate amounts of insulin to compensate for insulin resistance in peripheral tissues, primarily liver and muscle. Further, T2DM is characterized by the emergence of postprandial- and subsequently, fasting- hyperglycemia. In the liver, insulin resistance is manifested by glucose overproduction during the basal state despite fasting hyperinsulinemia, combined with impaired hepatic response to the normal elevation in postprandial insulin. In muscle, insulin resistance manifests as impaired postprandial glucose uptake.

A number of preclinical reports demonstrated exendin-4-mediated restoration of function and mass of insulin-secreting islets in the rodent pancreas [32,50,52-56]. These models of T2DM and obesity include the obese (ob/ob) mouse that is deficient in the hormone leptin and expresses insulin resistance and impaired insulin tolerance, the db/db mouse that has a defect in leptin signaling and expresses insulin resistance, hypertriglyceridemia and has impaired glucose tolerance, the partial-pancreatectomized rodent model (rats or mice), the Goto-Kakizaki rat that is genetically predisposed to a neonatal β-cell mass deficiency, the insulin-resistant obese fa/fa diabetic Zucker rat, the nonda-
betic insulin-resistant obese fa/fa Zucker rat, and spontaneously-diabetic Rhesus monkeys. For example, in mice genetically predisposed to develop diabetes (db/db), exendin-4 increased β-cell proliferation and islet mass, ameliorated the normal development of hyperglycemia, improved insulin secretion, and reduced HbA1c. Exendin-4 also blocked β-cell apoptosis, increased pancreatic expression of transcription factors, and enhanced islet neogenesis. Due to the difficulty of reproducing this type of experiment in humans, it is not known whether the same mechanism is active in patients with T2DM.

Glucose-dependent insulinotropism, the ability of agents to stimulate insulin secretion during euglycemia or hyperglycemia, but not during hypoglycemia, was elucidated in some of the preclinical models of diabetes described above [39,44,49]. For example, in diabetic db/db mice, chronic exendin-4 administration resulted in fasting serum insulin concentrations notably higher than with vehicle treatment under conditions of hyperglycemia [44]. HbA1c and fasting glucose concentrations were significantly reduced, but did not quite reach normoglycemic levels, with no evidence of hypoglycemia. Another preclinical study investigated whether the previously-described effects of exendin-4 on insulin sensitivity, appetite, and body weight were distinct from its antihyperglycemic effects [53]. In this study, exendin-4 increased β-cell mass to a greater extent in nondiabetic insulin-resistant obese fa/fa Zucker rats than would be expected in animals of comparable insulin-resistance, suggesting a direct trophic effect of exendin-4 on pancreatic islet neogenesis, independent of improvements in metabolic parameters. This study was the first to show that exendin-4 could improve insulin sensitivity in an environment of insulin resistance, partly due to reductions in food intake and partly independent of changes in body weight and ambient glycermia.

Exendin-4 and Body Weight in Animal Models of Diabetes and/or Obesity

In nonclinical diabetes models, weight loss or blunted weight gain are consistently associated with exendin-4 treatments [39,46,47,48]. Studies have extended these findings to include obese, normoglycemic animal models. For example, exendin-4 treatment for 56 days reduced food intake and slowed weight gain in obese fa/fa Zucker rats [47]. Corresponding reductions in HbA1c, fasting glucose, and fasting insulin also occurred. In a later study, acute exendin-4 administration dose-dependently suppressed food intake in normoglycemic mice and rats fed a high fat diet, while chronic, continuous exendin-4 infusion significantly slowed body weight gain, decreased fat mass, and spared lean tissue [48]. Food intake, total cholesterol, triglycerides and insulin levels were all significantly reduced. These data suggest that exendin-4 has an effect on metabolic pathways regulating food ingestion.

EXENATIDE (SYNTHETIC EXENDIN-4) CLINICAL PHARMACOLOGY AND EXPLORATORY INVESTIGATIONS

Overview

Clinical pharmacology studies have been conducted using synthetic exendin-4 (exenatide) administered as subcutaneous injections or intravenous infusions. These studies have identified the appropriate dosing approach for clinical use, and explored the mechanisms of action in humans. Initial dosing strategies explored single bolus, continuous infusion, and twice (BID) and thrice (TID) daily subcutaneous administration before meals. In these studies, subcutaneous injections of 10-mcg exenatide twice daily (ExBID) demonstrated a consistent pattern of pharmacokinetics and pharmacodynamic responses, with transient, mild-to-moderate nausea as the primary side effect [60-65]. There was a minimal
dependence of exenatide pharmacokinetic profiles on body weight, supporting development of a fixed dosage regimen for ExBID [59,62]. These studies also found utility in starting patients on a 5-mcg exenatide BID dose, generally for 4 weeks, before increasing to the maintenance dose of 10-mcg BID [66]. This graduated approach mitigated much of the nausea and vomiting observed when initiating directly with the 10-mcg BID dose.

The mechanisms of action elucidated in nonclinical experiments with exendin-4 were largely confirmed in early human studies in both healthy individuals and in patients with type 2 diabetes. In patients with T2DM, exenatide slowed gastric emptying; reduced fasting hyperglycemia and hyperglucagonemia; stimulated glucose-dependent insulin secretion (pancreatic β-cell function); attenuated postprandial excursions of glucose, insulin, and glucagon; inhibited food intake; and reduced body weight. The integrated effects of these mechanisms are likely important for the clinical efficacy of ExBID.

**Studies on Gastric Emptying and Satiety**

The effects of exenatide on gastric emptying in patients with T2DM are best understood within the context of the important role the rate of nutrient delivery from the stomach to the small intestine plays in the extent of postprandial glucose excursions [67,68]. One of the main confounders in understanding the pathophysiology of gastric emptying in diabetes is hyperglycemia itself, as elevated glucose concentrations in healthy individuals slow the rate of gastric emptying in order to moderate postprandial glucose excursions [67]. Thus the gastric emptying rate in the face of diabetic hyperglycemia may be considered pathophysiological, as gastric emptying is relatively accelerated in patients with diabetes, compared with the usually expected slowing of gastric emptying that occurs in healthy individuals under similar hyperglycemic conditions. In patients with T2DM (without severe autonomic neuropathy), gastric emptying rates are often accelerated compared with healthy individuals. Conversely, patients with T2DM and severe autonomic neuropathy often have reduced gastric emptying (gastroparesis).

For exenatide, slowing of gastric emptying and reduced food intake were first established as important mechanisms-of-action in nonclinical experiments [44,47]. Later, clinical pharmacology studies confirmed slowed gastric emptying in patients with T2DM given various exenatide doses including clinically-relevant doses [59-62,69,70]. Using scintigraphy, 5-days of ExBID was shown to slow gastric emptying of both the solid and the liquid components of a meal [70]. The $T_{50}$ (time to achieve 50% stomach emptying) for solid meal components was 169 minutes, significantly slower than the $T_{50}$ of 60 minutes for PBO. The $T_{50}$ for liquid meal components was 114 minutes, also significantly slower than the $T_{50}$ of 34 minutes for PBO. Thus, ExBID increased the $T_{50}$ 3-fold for both solids and liquids compared with PBO.

Clinical studies have also documented a significant reduction of food intake and patient reports of increased satiety after exenatide administration in both normo- and hyperglycemic individuals [69,71,72]. In lean (mean BMI 25 kg/m²), healthy young adults, bolus injections of 10 mcg exenatide reduced caloric intake, overall food intake, and ingestion of proteins, carbohydrates, and total fat, compared with placebo [71]. When exenatide was injected 60 minutes prior to a standardized meal, mean caloric intake was significantly lower (463 kcal compared with 672 kcal for placebo). Postprandial glucose concentrations at 60 and 120 minutes after meals were also reduced. In another study enrolling healthy volunteers, exenatide acutely reduced food intake and slowed gastric emptying [72]. Subjects consumed 19% fewer calories at a free-choice buffet lunch with exenatide than with placebo (867±79 kcal versus 1,075±93 kcal, respectively; p=0.012). Further, T2DM patients administered exenatide had significantly reductions in caloric intake, postprandial triglycerides, and body weight, compared to treatment with the DPP-4 inhibitor sitagliptin [69]. Exenatide reduced total caloric intake by -134±97 kcal compared with an increase of +130±97 kcal with sitagliptin.

**Integrated Effects of Exenatide on Glycemia**

In patients with T2DM, exenatide rapidly lowers both fasting and postprandial plasma glucose by multiple mechanisms [60-61,69,72,74]. In the postprandial state, exenatide slows gastric emptying to modulate the rate of nutrient absorption and moderate the extent of postprandial glucose excursions. Representative dose-response profiles found during these early exenatide clinical studies for the simultaneous changes in glucose, insulin, and glucagon occurring after an exenatide injection demonstrated these actions at clinically-relevant doses (Fig. 5). In two separate early-stage, 28-day clinical trials, exenatide also dose-dependently reduced HbA1c [60,63].

Two other clinical pharmacology studies investigated the relative contributions of slowed gastric emptying, enhanced insulin secretion, glucagon suppression, and splanchic and peripheral glucose metabolism on postprandial glucose excursions in patients with T2DM after intravenous exenatide administration [75,76]. Glucose retained within the splanchic bed consists of glucose taken-up and stored by the liver, glucose metabolized by gastrointestinal tissues, and glucose remaining in the gastrointestinal tract. Infusion of exenatide with an oral glucose bolus or a mixed meal attenuated the rate of glucose appearance in the circulatory system. Exenatide decreased endogenous glucose release from the liver by approximately 45% and increased glucose retention in the
splanchnic area. However, exenatide did not increase tissue sensitivity to insulin, nor did it alter the rate of total body glucose disposal.

In multiple clinical pharmacology studies in patients with T2DM, exenatide was shown to modulate fasting serum insulin and glucagon in a manner dependent upon exenatide dose and ambient glucose concentrations [60-62,64,69,77-80]. Both acute and chronic exenatide therapy improved β-cell secretory function (i.e., insulin secretion in response to hyperglycemia). In patients with T2DM with a blunted first phase insulin secretory response after acute elevation of blood glucose levels, intravenous exenatide in the therapeutic range restored the normal first phase insulin secretory response [79]. Exenatide also augmented the second-phase insulin secretory response. Of note, the overweight patients with T2DM enrolled in this study had a mean HbA1c of 6.6%, indicating good glycemic control at baseline.

The ability of exenatide to dose-dependently suppress inappropriately-elevated glucagon secretion was demonstrated in patients with T2DM in a number of clinical pharmacology studies [61,62,63,69,80]. Exenatide-mediated reductions in plasma glucagon concentrations under fasting conditions support the hypothesis that suppression of glucagon secretion is not merely a consequence of the slowing of nutrient presentation to the small intestine (gastric emptying).

Degn et al. [81] explored glucose-dependent insulin secretion and the counter-regulatory response to hypoglycemia in healthy volunteers given an intravenous infusion of exenatide or PBO (Fig. 6). In the presence of euglycemic hyperinsulinemia, insulin secretory rates with exenatide were significantly (3.5-fold) higher than with PBO. During hypoglycemia, insulin secretory rates declined similarly and rapidly in both groups. Glucagon was markedly more suppressed with exenatide than with PBO (~50% lower) under conditions of euglycemia. During worsening of hypoglycemia, glucagon increased progressively with both treatments, but to a significantly greater extent with exenatide. Plasma glucose recovery time was equivalent for both treatments. During the recovery interval, glucagon response was equivalent in both treatment arms. Circulating levels of cortisol, epinephrine, norepinephrine, and growth hormone were similar between treatment arms, indicating preservation of the counter-regulatory response to hypoglycemia during exenatide exposure.

Fig. (5). Exenatide treatment for 5 days restored a more normal glycemic profile in patients with T2DM. Fasting plasma glucose (A), serum insulin (B), and (C) glucagon concentrations during the 8 hours following a single dose of placebo (n=11) or 0.1 μg/kg exenatide administered at t = 0 (n=12). Mean±SEM. (D, E, F) Postprandial plasma glucose (D), insulin (E), and glucagon (F) concentrations following a single dose of placebo or 0.1 μg/kg exenatide at t=0 followed by a standardized meal. Postprandial glucose: Placebo n=20; Exenatide n=20. Postprandial insulin: Placebo n=16; exenatide n=16. Postprandial glucagon: Placebo n=20; Exenatide n=20. (Adapted from reference [61]).
Fig. (6). Insulin secretory response and glucagon counterregulatory hormone response. Basal period: ~30 to 0 min. Infusion of exenatide or placebo commenced at 0 min. Glycemic steps: 0-120 min, euglycemia with plasma glucose at ~5.0 mmol/L; 120–180 min, hypoglycemia with plasma glucose at ~4.0 mmol/L; 180-240 min, hypoglycemia with plasma glucose at ~3.2 mmol/L ending in nadir of ~2.8 mmol/L; 270-360 min, recovery phase. Open circles, placebo treatment arm; Filled circles, exenatide treatment arm. Data are mean±SEM. N=11 per treatment arm. *P<0.05, exenatide versus placebo during the steady-state of the indicated glycemic interval. (Reprinted with permission from reference [82]).

Effects of Exenatide on CVD Risk Markers and in Fatty Liver Disease

Exenatide has been shown to have beneficial effects on cardiovascular biomarkers. Acute exenatide administration suppressed postprandial excursions of pro-atherogenic lipid and lipoprotein in overweight/obese adults with impaired glucose tolerance or recent onset T2DM [82,83]. Fifty-seven percent of these patients were being treated with statins for dyslipidemia. However, one injection of exenatide was still able to markedly reduce postprandial elevation of triglycerides, apolipoprotein B-48, apolipoprotein-CIII, remnant-like particles-cholesterol and remnant-like particles-triglyceride compared with baseline. In another study, Ex-BID significantly improved markers of oxidative stress (prostaglandin F2α) and cardiovascular inflammation (high sensitivity C-reactive protein [hsCRP]), independent of baseline HbA1c, body weight, and BMI [84].

ExBID also had beneficial effects on liver fat content in patients with type 2 diabetes, in whom nonalcoholic fatty liver disease is prevalent [85]. ExBID significantly increased plasma adiponectin, reduced hepatic fat content (from mean 12.1% to 4.7%), and plasma triglyceride concentrations (-38%), despite no significant change in body weight. In addition, the hepatic injury biomarkers aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were significantly decreased by ExBID, suggesting beneficial effects on fatty liver disease.

EXENATIDE BID EFFICACY IN LATE STAGE CLINICAL TRIALS

Overview

In controlled trials ranging in treatment duration from 12 to 52 weeks where HbA1c reduction was a primary endpoint, ExBID as monotherapy and in various combinations with MET, SFU, TZD, and insulins reduced mean HbA1c by ~0.8% to -1.7% in T2DM patients with mean baseline HbA1c values ranging from 7.5% to 10.2% (Tables 1 and 2) [86-120]. The percentage of patients with T2DM achieving HbA1c values ≤7% with ExBID ranged from 20% to 79%, depending upon the baseline characteristics of the patient populations, their concomitant medications, and the active treatment regimen. In a study where weight reduction was the primary endpoint, patients with T2DM with a mean baseline HbA1c of 7.7% still had mean HbA1c reductions of -0.6% more than PBO when ExBID was added to intensive lifestyle modification [121].

Meta-analyses of large clinical trials have demonstrated a positive correlation between baseline HbA1c and the magnitude of HbA1c response to therapy, independent of drug class or mechanism of action [122,123]. Consistent with these reports, ExBID-treated patients with a high mean baseline HbA1c of 10.2% had a mean HbA1c change of -1.74% after 24 weeks of treatment [86]. This cohort was insulin-naive,
had a mean diabetes duration of 9 years, and had failed to maintain glycemic control during treatment with MET plus SFU. In a study that allowed up-titration of insulin glargine to help achieve glycemic goals in all treatment arms, patients with a more moderate mean baseline HbA1c of 8.3% had a mean HbA1c reduction of -1.74% after 30 weeks of ExBID treatment [90]. Notably, these patients had a longer mean diabetes duration (12 years) than in the Bergenstal et al. [86] study and had failed to achieve glycemic control on more aggressive therapy (insulin glargine with or without MET±TZD). A post hoc analysis of pooled data from 17 ExBID clinical trials encompassing 2,096 patients found reductions in glycemic parameters and body weight across a wide range of background antidiabetes therapies [124].

Body weight reductions have consistently been associated with ExBID therapy, despite wide variability in T2DM duration and patient characteristics at baseline, concomitant medications, and study designs (Tables 1 and 2) [86-120]. Mean weight change with ExBID ranged from -1.2 kg to -8.0 kg in exposure periods ranging from 12 to 52 weeks. The proportion of ExBID-treated patients who had reductions in both HbA1c and body weight was reported in two controlled trials: 66% versus 36% with PBO [99] and 71% versus 54% with PBO [107]. A small percentage of patients may gain weight while receiving exenatide therapy.

Pivotal Clinical Trials, Pivotal Trial Extensions, and Monotherapy

The three primary, 30-week, PBO-controlled exenatide pivotal trials were conducted in patients with T2DM not achieving glycemic control with MET and/or SFU [92,95,105]. Treatment with ExBID resulted in mean HbA1c reductions ranging from -0.8 to -0.9% (Fig. 7). For patients treated with ExBID+SFU, when baseline HbA1c was <9%
the mean HbA1c change from baseline was \(-0.65\%\) and when baseline HbA1c was \(\geq 9\%\) the mean HbA1c change was \(-1.2\%\) [92]. For patients treated with ExBID+MET+SFU, when baseline HbA1c was <\(9\%\) the mean HbA1c change from baseline was \(-0.5\%\) and when baseline HbA1c was \(\geq 9\%\) the mean HbA1c change was \(-1.3\%\) [105]. Thus, ExBID reduced HbA1c to a greater extent in patients with higher baseline HbA1c, ie, worse glycemic control. The percentage achieving an HbA1c \(\leq 7\%\) after 30 weeks of ExBID treatment in these pivotal trials ranged from 30% to 46%. These patients also had progressive body weight reductions ranging from \(-1.6\) to \(-2.8\) kg. These improvements in glycemic control and body weight are especially notable, because no specific diet or exercise counseling, nor caloric restriction, were required by the study protocols.

A series of reports followed patients with T2DM originally enrolled in these first three ExBID pivotal trials during open-label extensions with up to 3.5 years of exposure (Tables 1 and 2, Fig. 8) [87,93,106,110,111]. The majority of ExBID-treated patients with T2DM who continued therapy maintained HbA1c reductions in combination with progressive weight loss, with 84% of patients reporting weight loss at Week 104 (2-year evaluable population N=521; 54% completed) [94]. After 3 years of ExBID, patients with T2DM on a background of MET, SFU, or MET+SFU had a mean HbA1c reduction of \(-1.0\%\), and 46% achieved an HbA1c \(\leq 7\%\) [106]. The sustained nature of the glycemic control associated with ExBID therapy may, in part, reflect effects on pancreatic \(\beta\)-cell secretory function, as evidenced by sustained improvements in HOMA-B out to 3 years. Fifty percent lost \(\geq 5\%\) of baseline body weight and 68% had reductions in both HbA1c and weight. This is in contrast to the weight gain associated with many other antidiabetic agents as glycemia improves [125]. After 3.5 years of therapy, 10-mcg ExBID therapy significantly improved a number of cardiovascular risk factors: mean change from baseline was \(-12\%\) for triglycerides, \(-6\%\) for LDL-C, \(-5\%\) for total cholesterol, +24% for HDL-C, \(-2\%\) for systolic BP, and \(-4\%\) for diastolic BP [106]. The 25% of ExBID-treated patients who lost the most weight had the greatest improvements in triglycerides, HDL-C, and blood pressure. However, for the entire cohort there were minimal correlations with weight change. These data suggest that ExBID may improve overall cardiometabolic risk factors by mechanisms that are partially dependent on weight loss and partially weight-independent. Data also suggest a role for exenatide in improving cardiometabolic and hepatic biomarkers in patients with T2DM. Elevated serum ALT is a biomarker of hepatic injury, often caused by the nonalcoholic fatty liver disease associated with obesity and T2DM. After 3 years of ExBID, mean ALT in patients with elevated baseline ALT declined progressively (-26%) and 41% had ALT normalization. Although the 25% of patients who lost the most weight had the greatest reduction in ALT, weight change in the entire cohort was only mildly correlated with baseline ALT (r= -0.01) or ALT change r=0.31).

The efficacy of ExBID monotherapy in treatment-naive patients with T2DM was explored in two PBO-controlled
Clinical trials, one was preliminary [126] and one was phase 3 [108]. In the preliminary study, ExBID monotherapy significantly reduced hyperglycemia and body weight over 28 days of treatment. In the phase 3 study, 24 weeks of ExBID monotherapy significantly reduced mean HbA1c by -0.9%, compared with -0.2% in the PBO group. An HbA1c ≤7% was achieved by 46% with ExBID, compared with only 29% with PBO. Mean daily six-point self-monitored blood glucose concentrations were significantly reduced with ExBID monotherapy compared with PBO (daily mean change -27 mg/dL versus -5 mg/dL, respectively). In addition, β-cell function measured by HOMA-B improved by 28% in the ExBID group compared with 6% in the PBO group.

**Insulin Comparator Studies**

ExBID has generally demonstrated non-inferiority to insulin glargine and biphasic insulin aspart [86,88,94,102,109,127]. In addition, weight loss was associated with ExBID therapy, compared with weight maintenance or weight gain with insulin therapy. In one study, a strategy of aggressive insulin dose titration reduced HbA1c more with insulin than with ExBID, albeit with greater weight gain in the insulin group [86].

Recently, the data from four ExBID versus insulin comparator studies [94,102,109,127] were pooled (1423 patients) and analyzed [128]. Treatment ranged from 16 to 52 weeks in duration. Overall glycemic control with ExBID (mean HbA1c change -1.2%) was non-inferior to insulin (mean HbA1c change -1.1%) at 6 months, and patients who continued treatment through 52 weeks showed sustained reductions in HbA1c from baseline (ExBID, -1%; insulin, -0.9%). When stratified by HbA1c change from baseline tertiles, ExBID and insulin were associated with comparable reductions in each tertile, with the greatest mean reductions of -1.7% (ExBID) and -1.7% (insulin) observed in the tertile with the highest baseline HbA1c range (9.0% to 12.7%). ExBID was associated with weight loss (mean -2.0 kg) versus weight gain with insulin (mean +1.8 kg) at Week 26; the corresponding values at Week 52 were -3.1 kg vs +1.9 kg. Overall, more ExBID-treated patients (70%) experienced weight loss than did those treated with insulin (21%). For patients with an elevated systolic BP at baseline (≥130 mmHg), ExBID reduced systolic BP to a significantly greater extent than insulin (mean -8.1 vs -3.6 mmHg). The frequency of nocturnal, mild-to-moderate hypoglycemia was lower with ExBID (15%) than with insulin (29%).

**Other CVD Effects**

ExBID effects on BP were analyzed in more depth by pooling data from patients with T2DM treated in six comparator controlled (PBO or insulin) clinical trials of 24 to 52 weeks duration (Fig. 9) [129]. All patients continued existing antidiabetes, antihypertensive, and dyslipidemia medications. In the pooled analysis, 6 months of ExBID therapy was associated with a significantly greater reduction in systolic BP than was PBO or insulin. Patients with elevated baseline systolic BP (≥130 mmHg) appeared to drive the BP changes observed in the overall population. This subgroup had mean systolic BP reductions with ExBID of -8.3 mmHg versus -4.5 mmHg with PBO; and -8.3 mmHg with ExBID versus -4.2 mmHg with insulin. Although the majority of exenatide-treated subjects lost weight, weight loss was only weakly correlated with systolic BP change (r=0.09), again suggesting exenatide effects were not solely mediated by weight loss.

Clinical trial data from patients with T2DM treated with ExBID or insulin glargine on a background of MET for one year yielded additional insight into the complex metabolic changes associated with exenatide therapy [130,131]. Exenatide treatment reduced total body fat mass and improved the profile of biomarkers for CVD risk compared with insulin glargine. ExBID also significantly reduced post-meal proatherogenic triglycerides, apoB48, VLDL-C, and free fatty acid excursions, as well as the oxidative stress markers MDA and oxLDL-to-LDL ratio compared with insulin glargine. Body weight (-6%), waist circumference (-5%), and total body fat mass (-11%) were all reduced compared with insu-
lin glargine. In addition, there were significant changes in total adiponectin (+12%) and hsCRP (-61%) compared with insulin glargine. In contrast, insulin glargine only significantly reduced endothelin-1 (-7%) compared with ExBID. Notably, the adiponectin and hsCRP changes in the ExBID arm were independent of the changes in total fat mass (adiponectin: \( r = -0.224 \); hsCRP: \( r = -0.023 \)). One year of ExBID also significantly reduced hsCRP in two other comparator-controlled clinical trials [96,97].

Acute exenatide effects on postprandial lipids, remnant lipoproteins, and apolipoproteins in subjects with impaired glucose tolerance or recent onset T2DM were also reported by Schwartz et al. [82]. A single exenatide injection prior to a high-fat meal significantly reduced postprandial triglyceride, apoB48, apoCIII, non-esterified fatty acid, and remnant lipoprotein excursions, compared with PBO. Postprandial excursions of total apoB and LDL-C were not changed. These metabolic effects were not affected by the degree of ambient hyperglycemia nor by dyslipidemia treatment with statins.

STUDY ON THE FEASIBILITY OF CONTINUOUS EXENATIDE DOSING

In order to evaluate the feasibility of transitioning from twice daily to once weekly exenatide administration in humans, 12 patients with T2DM were also reported by Schwartz et al. [82]. A single exenatide injection prior to a high-fat meal significantly reduced postprandial triglyceride, apoB48, apoCIII, non-esterified fatty acid, and remnant lipoprotein excursions, compared with PBO. Postprandial excursions of total apoB and LDL-C were not changed. These metabolic effects were not affected by the degree of ambient hyperglycemia nor by dyslipidemia treatment with statins.

EXENATIDE ONCE WEEKLY (QW)

Overview

The formulation of exenatide into a 2-mg once weekly (ExQW) agent differs from ExBID due to encapsulation of the exenatide peptide within poly-(D,L-lactide-co-glycolide) microspheres (Fig. 10) [132]. After mechanical suspension and subcutaneous injection, ExQW microspheres hydrate in situ and adhere to each other to form an amalgam. A small amount of exenatide (1-2% of the total area under the plasma concentration-time curve) that is loosely bound to the amalgam surface reaches the circulatory system within the first few hours post-injection. Exenatide located in deeper interstices diffuses out more slowly with a \( T_{\text{max}} \) of approximately 2 weeks. Fully encapsulated exenatide, that is initially inaccessible to diffusion, releases with a \( T_{\text{max}} \) of approximately 7 weeks as the microspheres hydrolyze and are eliminated as carbon dioxide and water. Plasma exenatide concentrations reach the therapeutic range by 2 weeks post-injection and achieve steady state by 6 to 7 weeks post-injection.

In phase 3 clinical trials, 2-mg ExQW significantly reduced mean HbA1c by -1.3% to -1.9% during controlled treatment periods ranging from 24 to 30 weeks [113,114,116-118]. Mean body weight change ranged from -2.3 to -3.7 kg. Further, the proportion of ExQW-treated patients with reductions in both HbA1c and body weight ranged from 70% to 79%.

Initial Clinical Testing

The initial phase 2 clinical trial of ExQW evaluated effects in patients with T2DM randomized to ExQW or PBO for 15 weeks on a background of MET or diet/exercise [133]. By Week 2, plasma exenatide concentrations exceeded the minimally effective level (approximately 50 pg/ml) shown to reduce fasting plasma glucose concentrations and remained within the target therapeutic range throughout the remainder of the treatment period. ExQW patients had an HbA1c reduction of -1.7±0.3% compared with an HbA1c increase of 0.4±0.3% in the PBO group. In addition, 86% of patients in the ExQW group achieved an HbA1c<7%, compared with none in the PBO group. Mild nausea was the most frequent exenatide-associated adverse event (27% versus 15% with PBO). Of note, the incidence of injection site reaction was 7% with ExQW versus 0% with PBO.
Phase 3 Clinical Trials

Phase 3 ExQW clinical development in patients with T2DM is comprised of the DURATION (Diabetes therapy Utilization: Researching changes in HbA$_{1c}$, weight and other factors Through Intervention with exenatide QOnce weekly) program [134]. In the series of DURATION clinical trials completed to date, ExQW has been compared with ExBID (DURATION-1, -5), metformin (DURATION-4), sitagliptin (DURATION-2, -4), pioglitazone (DURATION-2, -4), liraglutide (DURATION-6), and titrated insulin glargine (DURATION-3) on background antidiabetes therapies of diet/exercise, MET alone, or combination OAD therapy (MET, SFU, TZD) (Tables 1 and 2) [86-120]. In controlled treatment periods of the DURATION trials (ranging from 24 to 30 weeks), ExQW significantly reduced mean HbA$_{1c}$ by -1.3% to -2.0% from mean baseline HbA$_{1c}$ values ranging from 8.3% to 8.6%. Mean body weight change ranged from -2.3 to -3.7 kg with ExQW treatment from mean baseline weight values ranging from 88 to 103 kg.

DURATION-1 and -5 directly compared ExQW with ExBID in patients treated with diet/exercise, MET alone, or combination OAD therapy [114,115]. ExQW significantly reduced fasting glucose (Fig. 11) and glucagon to a greater extent than ExBID. In contrast, ExBID reduced postprandial glucose excursions to a greater extent than ExQW. During the 30 week controlled portion of DURATION-1, ExQW reduced mean HbA$_{1c}$ by -1.9%. In the open-label extension, patients with T2DM treated with ExQW from baseline had HbA$_{1c}$ reductions of -2.0% at Week 52 [115], -1.7% at Week 104 [119], and -1.6% at Week 156 on a background of...
diet/exercise, MET, SFU, TZD, or any 2 OADs. Treatment with ExQW was associated with mean weight reductions of -3.7 kg at Week 30 [117], -4.1 kg at Week 52 [115], -2.6 kg at Week 104 [119], and -2.3 kg at Week 156. In DURATION-5, ExQW reduced mean HbA1c by -1.6% and body weight by -2.3 kg on a background of diet/exercise, MET, SFU, TZD, or any combination of the OADs [114].

The second study with long-term data from an open-label extension (DURATION-2) confirmed that glycemic control could be sustained for up to one year with ExQW [113,120]. At the end of the controlled treatment period treatment of 26 weeks, ExQW on a background of MET reduced mean HbA1c by -1.5%, compared with -1.6% at Week 52. The corresponding weight reductions were -2.3 kg and -1.8±0.5 kg, respectively [114,120].

In the DURATION-6 study, ExQW reduced mean HbA1c by -1.3% after 26 weeks of treatment, compared with -1.5% in the liraglutide treatment arm where the liraglutide cohort underwent a forced titration to the maximum approved dose. The HbA1c treatment difference was 0.2%, with a 95% confidence interval of 0.08% to 0.34%. Therefore, under the predefined study analysis requiring the upper limit of the HbA1c 95% confidence interval to be <0.25%, ExQW did not meet the primary endpoint of noninferiority to the maximum daily dose of liraglutide. Mean weight reduction was significantly greater in patients treated with liraglutide (-3.6 kg) than with ExQW (-2.7 kg). Both drugs reduced systolic BP, diastolic BP, and a number of cardiovascular risk factors to a similar extent.

In the only study to evaluate ExQW in drug-naïve patients (DURATION-4), mean HbA1c and body weight changes were -1.5% and -2.0 kg, respectively, after 26 weeks of treatment [118]. However, ExQW is not currently recommended for use as first line therapy in patients failing diet/exercise [135].

In the controlled DURATION trials, the proportion of ExQW-treated patients who had reductions in both HbA1c and body weight ranged from 67% to 79% [113,114,116-118]. In DURATION-2 [112], reductions in both HbA1c and body weight occurred in 70% with ExQW, 46% with sitagliptin, and 14% with pioglitazone on a background of MET. In DURATION-3 [116] reductions in both HbA1c and body weight occurred in 79% with ExQW versus 31% with insulin glargine, on a background of MET plus SFU. In DURATION-5 [114], reductions in both HbA1c and body weight occurred in 71% with ExQW compared with 51% with ExBID on a background of diet/exercise, MET, SFU, TZD, or a combination of 2 OADs. On the same background therapy, DURATION-1 [117] reported that 73% of ExQW-treated patients had reductions in both HbA1c and body weight, compared with 74% of ExBID-treated patients. In DURATION-4 [118], treatment-naïve patients had reductions in both HbA1c and body weight in 67% with ExQW, 69% with MET, 33% with pioglitazone, and 59% with sitagliptin.

**GLP-1 Receptor Agonism Versus Enhancing Endogenous Incretin Levels**

As described in the nonclinical sections of this review, the GLP-1 receptor agonist exenatide is resistant to degrada-

**EXENATIDE ADVERSE EVENTS IN CLINICAL TRIALS AND ROUTINE CLINICAL USE**

**Overview**

ExBID was approved for human use in 2005 by the U.S. Food and Drug Administration and there is a large clinical trial database of safety events available for analysis [137]. The most common side effects are gastrointestinal in nature, mild, and transient. Nausea is the most prevalent adverse event at drug initiation, and it tends to decrease in frequency with continued exenatide exposure.

Recently, MacConell et al. [137] published an integrated analysis of 5594 patients with T2DM from 19 comparator-controlled exenatide BID clinical trials. In this report, representing over 1500 patient-years of exposure, the exenatide BID safety profile was compared with the safety profile of a pooled comparator (PBO, insulin aspart, or insulin glargine) cohort treated for 12 to 52 weeks on background therapies of diet/exercise, MET, SFU, TZD, and OAD combinations. Both cohorts had comparable baseline characteristics. For the 3261 exenatide-treated subjects, 44% were female with a mean age of 56 years and a mean BMI of 32 kg/m². Mean baseline HbA1c was 8.3% and mean treatment exposure was 166 days. For the 2333 subjects in the pooled comparator cohort, 46% were female with a mean age of 56 years and a BMI of 32 kg/m². Mean HbA1c was 8.3% and mean treatment exposure time 171 days. No specific safety signals of concern were identified with exenatide use. Both cohorts had comparable rates of serious adverse events, discontinuations due to serious adverse events, and deaths (exenatide: 3.6%, 0.8%, and <0.1%, respectively; pooled comparator: 3.9%, 0.7%, and <0.1%, respectively). Consistent with the results from individual clinical trials, transient mild-to-moderate
nausea was the most frequent side effect associated with exenatide (36.9% versus 8.3% in the pooled comparator) (Fig. 12). Overall, gastrointestinal adverse events were more frequently observed with exenatide than with comparator treatment (51% versus 21%, respectively). Gastrointestinal adverse events were also the most common reason for discontinuation of clinical trial participation in the exenatide cohort. Vomiting had a composite frequency of 14% compared with 3% in the pooled comparator group, while diarrhea had a composite frequency of 11% versus 5% in the pooled comparator group. However, nausea and vomiting decreased over time in the exenatide group (independent of dose), with a substantial reduction in incidence rate after 8 weeks of treatment. Of the other most-frequent adverse events (≥5% frequency), only dizziness occurred significantly more frequently with exenatide than with comparator exposure (5% versus 3%, respectively).

In another integrated analysis, MacConell et al. published a preliminary report of adverse events from 4,328 patients with T2DM treated in 8 randomized phase 3 ExQW trials. The most frequent adverse events with ExQW were gastroin...
Table 1. Overview of Exenatide Phase 3 Clinical Trial Designs.

| Study Citation       | Study Dur (wk) | Double Blind? | Multi-National? (#countries) | Analysis Pop       | Mean Calc | NCT#   |
|----------------------|----------------|---------------|-------------------------------|--------------------|-----------|--------|
| **Exenatide BID**    |                |               |                               |                    |           |        |
| Bergenstal 2009 [86] | 24             | No            | No (US)                       | ITT & per protocol | Mean      | 00097877 |
| Blonde 2006 [87]     | 82             | No            | No (US)                       | ITT & completers  | Mean      | 00111540 |
| Bunck 2009 [88]      | 52             | No            | Yes (3)                       | ITT & evaluable    | Mean      | 00097500 |
| Bunck 2011 [89]      | 168            | No            | Yes (3)                       | ITT & evaluable    | Mean      | 00097500 |
| Buse 2011 [90]       | 30             | Yes           | Yes (5)                       | ITT                | LS Mean   | 00765817 |
| Buse 2009 [91]       | 26             | No            | Yes (15)                      | ITT & per protocol | LS Mean   | 00518882 |
| Buse 2004 [92]       | 30             | Yes           | No (US)                       | ITT & evaluable    | Mean      | 00039026 |
| Buse 2007 [93]       | 104            | No            | No (US)                       | ITT & completers  | Mean      | 00111540 |
| Davies 2009 [94]     | 26             | No            | No (UK)                       | ITT                | LS Mean   | 00360334 |
| DeFronzo 2005 [95]   | 30             | Yes           | No (US)                       | ITT & evaluable    | Mean      | 00039013 |
| Derosa 2010 [96]     | 52             | No            | No (Italy)                    | ITT                | Mean      | NA      |
| Derosa 2011 [97]     | 52             | No            | No (Italy)                    | ITT                | Mean      | NA      |
| Forti 2008 [98]      | 12             | No            | Yes (2)                       | Per protocol       | LS Mean   | 00359879 |
| Gallwitz 2011 [99]   | 26             | No            | No (Germany)                  | ITT                | LS Mean   | 00434954 |
| Gao 2009 [100]       | 16             | Yes           | Yes (4)                       | ITT & per protocol | LS Mean   | 00324363 |
| Gill 2010 [101]      | 12             | Yes           | Yes (2)                       | ITT & per protocol | LS Mean   | 00516074 |
| Heine 2005 [102]     | 26             | No            | Yes (13)                      | ITT & per protocol | LS Mean   | 00082381 |
| Kadokawa 2009 [103]  | 12             | Yes           | No (Japan)                    | ITT                | Mean      | 00382239 |
| Kadokawa 2011 [104]  | 24             | Yes           | No (Japan)                    | ITT                | LS Mean   | 00577824 |
| Kendall 2005 [105]   | 30             | Yes           | No (US)                       | ITT & evaluable    | Mean      | 00035984 |
| Klonoff 2008 [106]   | 156 / 182      | No            | No (US)                       | ITT & completers  | Mean      | 00111540 |
| Liukus 2010 [107]    | 26             | Yes           | Yes (5)                       | ITT                | LS Mean   | 00603239 |
| Moretto 2008 [108]   | 24             | Yes           | Yes (4)                       | ITT                | LS Mean   | 00381342 |
| Nauck 2007 [109]     | 52             | No            | Yes (13)                      | ITT & per protocol | Mean      | 00082407 |
| Ratner 2006 [110]    | 82             | No            | No (US)                       | ITT & completers  | Mean      | 00111540 |
| Riddle 2006 [111]    | 82             | No            | No (US)                       | ITT & completers  | Mean      | 00111540 |
| Zinman 2007 [112]    | 16             | Yes           | Yes (3)                       | ITT & per protocol | LS Mean   | 00099320 |
| **Exenatide QW**     |                |               |                               |                    |           |        |
| Bergenstal 2010 [113]| 26             | Yes           | Yes (3)                       | ITT & evaluable    | LS Mean   | 00637273 |
| Blevins 2011 [114]   | 24             | No            | No (US)                       | ITT & evaluable    | LS Mean   | 00877890 |
| Buse 2010 [115]      | 52             | No            | Yes (2)                       | ITT & evaluable    | LS & Geo Mean | 00308139 |
Table 1. Contd….

| Study Citation | Study Dur (wk) | Double Blind? | Multi-National? (#countries) | Analysis Pop | Mean Calc | NCT#* |
|----------------|---------------|--------------|-----------------------------|--------------|----------|-------|
| Buse 2011[^1]  | 26            | No           | Yes (21)                    | ITT          | LS Mean  | 01029886 |
| Diamant 2010 [116] | 26          | No           | Yes (15)                    | ITT          | LS Mean  | 00641056 |
| Drucker 2008 [117] | 30           | No           | Yes (2)                     | ITT & evaluable | LS & Geo Mean | 00308139 |
| MacConell 2011[^2] | 156         | No           | Yes (2)                     | Completers  | LS & Geo Mean | 00308139 |
| Russell-Jones 2012 [118] | 26          | Yes          | Yes (22)                    | ITT          | LS Mean  | 00676338 |
| Taylor 2011 [119] | 104          | No           | Yes (2)                     | ITT & Completers | LS Mean | 00308139 |
| Wysham 2011 [120] | 52           | No           | Yes (3)                     | Evaluable    | LS Mean  | 00637273 |

[^1] Additional information on these trials is available at clinicaltrials.gov

Abbreviations: BID, twice daily; Dur, duration; Geo, geometric; ITT, intent-to-treat; LS, least squares; NA, not applicable; NCT, national clinical trial database; NI, non-inferiority; Pop, population; QW, once weekly; ΔRx, change or different diabetes medication prior to randomization; S, superiority.

Table 2. Overview of Exenatide Phase 3 Clinical Studies.

| Study Citation | Ther Studied | BG Ther | DO (%) | ITT N | F (%) | White (%) | T2DM Dur (y) ±SD | BL HbA1c (%) ±SD | ΔHbA1c (%) ±SE | Achieved HbA1c ≤7% or <7% (%) | BL BMI (kg/m²) ±SD | BL Wt (kg) ±SD | ΔWt (kg) ±SE |
|----------------|--------------|---------|--------|-------|-------|------------|------------------|-----------------|----------------|-------------------------------|---------------------|----------------|-------------|
| Bergenstal 2009 [86] | ExBID | MET + SFU | 29.8 124 51.6 63.7 9±6 | 10.2±1.5 | -1.75 | 20 | 34±7 | 96.6±24 | -1.9 |
| Aspart QD | ExBID | MET + SFU | 16.1 124 51.6 67.7 8±6 | 10.1±1.8 | -2.34 | 26 | 34±7 | 96.9±25 | 2.8 |
| Aspart BID | ExBID | MET + SFU | 19.4 124 52.4 59.7 10±6 | 10.3±1.9 | -2.76 | 37 | 34±7 | 93.8±24 | 4.1 |
| Blonde 2006 [87] | ExBID | MET +/or SFU | 43.0 551 39 74 | 7±6 | 8.4±1.0 | -1.1±0.1 | 48 | 34±6 | 98±20 | -4.4±0.3 |
| Bunck 2009 [88] | ExBID | MET | 16.7 36 36.1 100 6±1 | 7.6±0.1 | -0.8±0.1 | NG | 31±1 | 90.6±2.1 | -3.6±0.6* |
| Glarg | ExBID | MET | 9.1 33 33.3 97 4±1 | 7.4±0.1 | -0.7±0.2 | NG | 30±1 | 92.4±2.4 | 1.0±0.8 |
| Bunck 2011 [89] | ExBID | MET | 44.4 36 36.1 100 6±1 | 7.6±0.1 | -1.0 | NG | 31±1 | 90.6±2.1 | -5.7±1.3* |
| Glarg | ExBID | MET | 48.5 33 33.3 97 4±1 | 7.4±0.1 | -0.5 | NG | 30±1 | 92.4±2.4 | 2.1±1.3 |
| Buse 2011 [90] | ExBID | Glarg ±MET and/or TZD | 19 137 49 75 12±7 | 8.32±0.85 | -1.74 ±0.1* | 60* | 34±6 | 95.4±20.4 | -1.8±0.3* |
| PBO | ExBID | MET ± SFU | 18 122 36 80 12±7 | 8.50±0.96 | -1.04 ±0.1 | 35 | 33±6 | 93.4±21.2 | 1.0±0.3 |
| Buse 2009 [91] | ExBID | MET ± SFU | 19.5 231 45 91 8±6 | 8.1±1.0 | -0.8±0.1 | 43 | 33±6 | 93.0±19.5 | -2.9±0.3 |

[^1] Additional information on these trials is available at clinicaltrials.gov

Abbreviations: BID, twice daily; Dur, duration; Geo, geometric; ITT, intent-to-treat; LS, least squares; NA, not applicable; NCT, national clinical trial database; NI, non-inferiority; Pop, population; QW, once weekly; ΔRx, change or different diabetes medication prior to randomization; S, superiority.
| Study Citation | Ther Citation | Ther Studied | BG Ther | DO (%) | ITT N (%) | F (%) | White (%) | T2DM Dur (y) ±SD | BL HbA1c (%) ±SD | ΔHbA1c (%) ±SE | Achieved HbA1c ≤7% or <7% (%) | BL BMI (kg/m²) ±SD | BL Wt (kg) ±SE | ΔWt (kg) ±SE |
|----------------|---------------|--------------|---------|--------|-----------|------|----------|-----------------|-----------------|-------------|--------------------------|-----------------|----------|-------------|
| Buse 2004 [92] | ExBID SFU     | 29.5        | 129     | 42.6   | 59.7      | 7±7  | 8.6±1.2  | -0.9 ±0.1*      | 34.2*           | 33±6        | 95±18                     | -1.6 ±0.3*       | -         |             |
|                | 5 mcg ExBID   | 24.0        | 125     | 40.8   | 61.6      | 6±5  | 8.5±1.1  | -0.5 ±0.1*      | 26.7*           | 303±6       | 95±22                     | -0.9±0.3         | -         |             |
|                | PBO           | 39.8        | 123     | 37.4   | 66.7      | 6±5  | 8.7±1.2  | 0.1±0.1         | 7.7             | 34±5        | 99±18                     | -0.6±0.3         | -         |             |
| Buse 2007 [93] | ExBID         | 45.7        | 521     | 41.0   | 74        | 8±6  | 8.4±1.1  | -1.1±0.1        | 50              | 34±6        | 99±20                     | -4.7±0.3         | -         |             |
| Davies 2009 [94] | ExBID MET +/or SFU | 16.1    | 118     | 29.7   | NG        | 9±5  | 8.7±0.7  | -1.25±0.09      | NG              | 35±6        | 101.4±19.8                | -2.7±0.3*        | -         |             |
|                | Glarg          | 10.3        | 117     | 33.6   | NG        | 8±4  | 8.5±0.7  | -1.26±0.09      | NG              | 34±5        | 97.6±16.4                | 3.0±0.3          | -         |             |
| DeFronzo 2005 [95] | ExBID MET | 17.7        | 113     | 39.8   | 79.6      | 5±5  | 8.2±1.0  | -0.8 ±0.1*      | 46*             | 34±6        | 101±20                   | -2.8 ±0.5*        | -         |             |
|                | 5 mcg ExBID   | 18.2        | 110     | 48.2   | 77.3      | 6±6  | 8.3±1.1  | -0.4 ±0.1*      | 32*             | 34±6        | 100±22                   | -1.6 ±0.4*        | -         |             |
|                | PBO           | 21.2        | 113     | 40.7   | 72.6      | 7±6  | 8.2±1.0  | 0.1±0.1         | 13              | 34±6        | 100±19                   | -0.3±0.3         | -         |             |
| Derosa 2010 [96] | ExBID MET | 6.3         | 63      | 52.4   | 100       | NG  | 8.8±0.7  | -1.5            | NG              | 29±2        | 82.0±8.3                  | -8.0             | -         |             |
|                | Gli           | 12.3        | 65      | 49.2   | 100       | NG  | 8.9±0.8  | -1.8            | NG              | 29±1        | 82.4±9.1                  | 4.3              | -         |             |
| Derosa 2011 [97] | ExBID MET | 8.8         | 57      | 50.9   | 100       | NG  | 8.7±0.7  | -1.2            | NG              | 28±1        | 80.2±7.5                  | -5.1             | -         |             |
|                | Gli           | 9.3         | 54      | 51.9   | 100       | NG  | 8.8±0.8  | -1.4            | NG              | 29±1        | 81.4±8.1                  | -0.9             | -         |             |
| Forti 2008 [98] | ExBID MET ± SFU ± TZD | 11.1    | 190     | 58.4   | 41.0      | 9±6  | 8.4±0.9  | -1.2±0.1        | 45.1            | 31±4        | 82.7±16.1                | -1.3±0.2         | -         |             |
|                | ExBID at L, D | 16.0        | 187     | 51.3   | 45.0      | 8±6  | 8.5±1.0  | -1.1±0.1        | 32.6            | 31±4        | 81.8±14.2                | -1.1±0.2         | -         |             |
| Gallwitz 2011 [99] | ExBID Aspart | 25.4        | 181     | NG      | 5±4       | 7.9±0.8 | -1.00          | 49.2            | 33±4        | NG                      | -4.1±0.2*        | -         |             |
|                | Gao 2009 [100] | ExBID MET ± SFU | 17.5  | 234     | 52      | 0       | 8±6  | 8.3±1.0  | -1.2*           | 48*             | 26±3        | 69.6±11.2                | -1.2*            | -         |             |
|                | PBO           | 20.8        | 173     | NG      | 5±5       | 7.9±0.9 | -1.14          | 56.6            | 33±4        | NG                      | 1.0±0.2          | -         |             |
| Gill 2010 [101] | ExBID MET +/or TZD | 17.5    | 234     | 52      | 0       | 8±6  | 8.3±1.0  | -0.4            | 17              | 26±3        | 67.9±11.0                | 0.1             | -         |             |
|                | PBO           | 21.4        | 28      | 32      | 86       | 7±4  | 7.5±0.9  | NG              | NA              | 30±3        | 91.6±15.2                | -1.8±0.4*        | -         |             |
| Heine 2005 [102] | ExBID MET + SFU | 19.1        | 282     | 45.0   | 79.8      | 10±6 | 8.2±1.0  | -1.1            | 46              | 31±4        | 87.5±16.2                | -2.3*            | -         |             |
|                | Glarg         | 9.4         | 267     | 43.4   | 80.5      | 9±6  | 8.3±1.0  | -1.1            | 48              | 31±5        | 88.3±17.9                | +1.8             | -         |             |
| Kadowaki 2009 [103] | ExBID 5.0 mcg ExBID | 16.2        | 38      | 37.8   | 0       | 10±6  | 7.9±0.9  | -1.4 ±0.1*      | 79.4*           | 26±5        | 70.3±15.9                | -1.3±0.3         | -         |             |
|                | ExBID 2.5 mcg ExBID | 10.8      | 37      | 32.4   | 0       | 11±6  | 7.9±0.8  | -1.2 ±0.1*      | 71.4*           | 25±3        | 65.6±9.8                 | -0.2±0.3         | -         |             |
|                | PBO           | 8.1         | 38      | 29.7   | 0       | 15±11 | 8.0±0.8  | -0.9 ±0.1*      | 50.0*           | 24±3        | 64.9±11.6                | -0.08±0.2        | -         |             |
|                | PBO           | 2.5         | 40      | 25.0   | 0       | 12±6  | 8.1±0.7  | 0.02±0.1        | 5.1             | 26±5        | 71.1±14.0                | -0.7±0.2         | -         |             |
### Table 2. Contd….

| Study Citation | Ther Studied | BG Ther | DO (%) | ITT N | F (%) | White (%) | T2DM Dur (y) ±SD | BL HbA1c (%) ±SD | $\Delta$HbA1c (%) ±SE | Achieved HbA1c ≤7% or <7% (%) | BL BMI (kg/m²) ±SD | BL Wt (kg) ±SE | $\Delta$Wt (kg) ±SE |
|----------------|--------------|---------|--------|-------|-------|------------|-----------------|-----------------|----------------|-------------------|-----------------|---------------|----------------|
| Kadowaki 2011 [104] | ExBID SFU ± MET or SFU ± TZD | 27.4 | 72 | 31.9 | 0 | 12±7 | 8.2±1.0 | -1.6* ±0.1 | 71.0* | 26±4 | 69.1±11.2 | -1.5 ±0.3* |
| | 5 mcg ExBID | 9.7 | 72 | 31.9 | 0 | 12±6 | 8.3±0.8 | -1.3 ±0.1* | 67.1* | 25±4 | 67.0±11.5 | -0.4±0.3 |
| | PBO | 5.7 | 35 | 31.4 | 0 | 12±7 | 8.1±0.9 | -0.3±0.2 | 15.2 | 26±4 | 70.3±13.3 | -0.5±0.4 |
| Kendall 2005 [105] | ExBID MET + SFU | 17.8 | 241 | 40.7 | 66.4 | 9±6 | 8.5±1.1 | -0.8 ±0.1* | 30* | 34±6 | 98±21 | -1.6 ±0.2* |
| | 5 mcg ExBID | 15.9 | 245 | 40.8 | 69.0 | 9±6 | 8.5±1.0 | -0.6 ±0.1* | 24* | 33±6 | 97±19 | -1.6 ±0.2* |
| | PBO | 23.9 | 247 | 44.1 | 68.4 | 9±6 | 8.5±1.0 | 0.2±0.1 | 7 | 34±5 | 99±19 | -0.9±0.2 |
| Klonoff 2008 [106] | ExBID MET, + SFU | 58.8 | 527 | 36 | 83 | 8±6 | 8.2±1.0 | -1.0±0.1 | 46 | 34±5 | 99±18 | -5.3±0.4 |
| Liukus 2010 [107] | ExBID TZD ± MET | 14 | 111 | 40 | 57 | 6±4 | 8.2±0.9 | -0.8 ±0.2* | 49 | 34±6 | 94.5±17.8 | -1.4±0.6 |
| | PBO | 7 | 54 | 43 | 61 | 6±5 | 8.3±0.9 | -0.1±0.2 | 36 | 33±5 | 92.6±18.0 | -0.8±0.7 |
| Moretto 2008 [108] | ExBID D/E | 14 | 78 | 38 | 72 | 2±3 | 7.8±1.0 | -0.9 ±0.1* | 46* | 31±5 | 86±16 | -3.1 ±0.3* |
| | 5 mcg ExBID | 13 | 77 | 48 | 65 | 2±3 | 7.9±1.0 | -0.7 ±0.1* | 48* | 32±5 | 85±15 | -2.8 ±0.3* |
| | PBO | 12 | 77 | 45 | 66 | 1±2 | 7.8±1.0 | -0.2±0.1 | 29 | 32±5 | 86±16 | -1.4±0.3 |
| Nauk 2007 [109] | ExBID MET + SFU | 21.3 | 253 | 47 | NG | 10±6 | 8.6±1.0 | -1.0±0.1 | 32* | 31±4 | 85.5±15.7 | -2.5 ±0.2* |
| | Aspart | 10.1 | 248 | 51 | NG | 10±6 | 8.6±1.1 | -0.9±0.1 | 24 | 30±4 | 83.4±15.6 | 2.9±0.2 |
| Ratn er 2006 [110] | ExBID MET | 39 | 150 | 31 | 86 | 5±5 | 8.1±1.0 | -1.3±0.1 | 59 | 34±6 | 102±21 | -5.3±0.8 |
| Riddle 2006 [111] | ExBID SFU ± MET | 45 | 401 | 39 | 75 | 8±6 | 8.4±1.0 | -1.0±0.1 | 44 | 34±6 | 99±21 | -4.0±0.3 |
| | ExBID TZD ± MET | 28.9 | 121 | 46.3 | 85.1 | 7±5 | 7.9±0.9 | -0.9 ±0.1* | 62* | 34±5 | 97.5±18.8 | -1.8 ±0.3* |
| | PBO | 14.3 | 112 | 42.9 | 82.1 | 8±6 | 7.9±0.8 | 0.1±0.1 | 16 | 34±5 | 96.9±19.0 | -0.2±0.3 |
| Exenatide QW | ExQW MET | 20.6 | 160 | 44 | 33 | 6±5 | 8.6±1.2 | -1.5* | -58* | 32±5 | 89±20 | -2.3* |
| | 100 mg SITA | 13.3 | 166 | 48 | 30 | 5±4 | 8.5±1.2 | -0.9 | -30 | 32±5 | 87±20 | -0.8 |
| | 45 mg PIO | 20.6 | 165 | 52 | 39 | 6±5 | 8.5±1.1 | -1.2 | -42 | 32±6 | 88±20 | 2.8 |
| Bergenstal 2010 [113] | ExQW D/E, MET, SFU, TZD or any comb | 15.5 | 129 | 40 | 63 | 7±5 | 8.5±1.1 | -1.6 ±0.1* | 58.1* | 34±6 | 97.0±20.7 | -2.3±0.4 |
| | ExBID | 22.8 | 123 | 45 | 55 | 7±5 | 8.4±1.2 | -0.9±0.1 | 30 | 33±5 | 94.3±18.9 | -1.4±0.4 |
Table 2. Contd….

| Study Citation | Ther Citation | Ther Studied | BG Ther | DO (%) | ITT N | F (%) | White (%) | T2DM Dur (y) ±SD | BL HbA1c (%) ±SD | ΔHbA1c (%) ±SE | Achieved HbA1c ≤7% or <7% (%) | BL BMI (kg/m²) ±SD | BL Wt (kg) ±SD | ΔWt (kg) ±SE |
|----------------|---------------|--------------|---------|--------|-------|-------|-----------|----------------|----------------|--------------|--------------------------|----------------|---------------|-------------|
| Buse 2010 [115] | ExQW | D/E, MET, SFU, TZD or 2 OAD | 19 | 148 | 43 | 83 | 7±6 | 8.3±1.0 | -2.0 | 71 | 35±5 | 103±19 | -4.1 |
| DURATION-1 | ExBID then ExQW | 18 | 147 | 47 | 74 | 6±5 | 8.2±0.9 | -2.0 | 71 | 35±5 | 102±20 | -4.5 |
| Buse 20111 | ExQW | MET, SFU, TZD, or any comb | 13.2 | 461 | 44.9 | 83.3 | 8±6 | 8.4±1.0 | -1.3 | 52.3 | 32±6 | 90.9±19.5 | -2.7 |
| | LIRA | 13.1 | 450 | 45.6 | 81.8 | 9±7 | 8.4±1.0 | -1.5 | 60.2 | 32±5 | 91.1±19.1 | -3.6 |
| Diamant 2010 [116] | ExQW | MET ± SFU | 10.3 | 233 | 48 | 82 | 8±6 | 8.3±1.1 | -1.5 | 60* | 32±5 | 91.2±18.6 | -2.6 ±0.2* |
| | Glarg | 6.3 | 223 | 45 | 85 | 8±6 | 8.3±1.0 | -1.3±0.1 | 48 | 32±5 | 90.6±16.4 | 1.4±0.2 |
| Drucker 2008 [117] | ExQW | D/E, MET, SFU, TZD or 2 OAD | 13.5 | 148 | 45.0 | 83 | 7±6 | 8.3±1.0 | -1.9 | 77* | 35±5 | 102±19 | -3.7±0.5 |
| | ExBID | 11.6 | 147 | 49.0 | 73 | 6±5 | 8.3±1.0 | -1.5±0.1 | 61 | 35±5 | 102±21 | -3.6±0.5 |
| MacConell 20112 | ExQW | D/E, MET, SFU, TZD or 2 OAD | 34 | 295 | NG | NG | 7±5 | 8.2±1.0 | -1.6 | 57 | NG | 101±18 | -2.3 |
| Russell-Jones 2012 [118] | ExQW | D/E | 15.3 | 248 | 44 | 68.1 | 3±3 | 8.5±1.2 | -1.5±0.1 | 63 | 31±5 | 88±19 | -2.0±0.2 |
| | MET | 13.4 | 246 | 37 | 65.0 | 3±4 | 8.6±1.2 | -1.5±0.1 | 55 | 31±6 | 86±20 | -2.0±0.2 |
| | PIO | 18.4 | 163 | 41 | 67.5 | 3±4 | 8.5±1.2 | -1.6±0.1 | 61 | 31±5 | 86±18 | 1.5±0.3 |
| SITA | 14.1 | 163 | 42 | 69.3 | 3±4 | 8.5±1.3 | -1.2±0.1 | 43 | 32±5 | 89±19 | -0.8±0.3 |
| Taylor 2011 [119] | ExQW | D/E, MET, SFU, TZD or 2 OAD | 27 | 295 | 47 | 79 | 7±5 | 8.2±1.0 | -1.7±0.1 | 60 | 35±5 | 101±19 | -2.6±0.5 |
| Wysham 2011 [120] | ExQW | SITA then ExQW | 35.6 | 160 | 43 | 32 | 6±5 | 8.6±1.2 | -1.6±0.1 | 58 | 32±5 | 90±19 | -1.8±0.5 |
| | SITA then ExQW | 21.7 | 166 | 42 | 35 | 6±5 | 8.5±1.1 | -1.8±0.5 | 53 | 32±5 | 88±21 | -1.1±0.3 |
| | PIO then EQW | 39.4 | 165 | 49 | 39 | 6±5 | 8.4±1.0 | -1.6±0.1 | 59 | 32±5 | 86±21 | -3.0±0.3 |

Note: when ‘ExBID’ is listed without dose, dose was 10 mcg BID. When ExQW listed without dose, dose was 2 mg.

*aP<0.05 improvement in HbA1c or weight versus control group.

*Portions of table adapted from: Aroda V, Henry R, Han J, et al. A meta-analysis and systematic review of the efficacy of GLP-1 receptor agonists and DPP-4 inhibitors. Clin Ther. 2012;34:1247-58.e22
Accidental Overdosing

Several reports have described the adverse events associated with exenatide overdosing [138,139]. During one clinical trial, three patients were accidently injected with approximately 100-mcg of exenatide [138]. All three presented with severe nausea and vomiting, and one of them experienced severe hypoglycemia that resolved with intravenous administration of 5% dextrose. All three patients recovered without further sequelae. In another report, Cohen et al. [139] discussed the emergency room presentation of a 40-year-old morbidly obese woman with T2DM who self-injected 90-mcg of exenatide in addition to her usual morning medications. The patient presented with dizziness, weakness, nausea, one episode of vomiting, normal vital signs, normal laboratory values, and fasting blood glucose ranging from 84 to 109 mg/dL upon hourly monitoring. Treatment consisted of metoclopramide intravenously. The patient did not become hypoglycemic and fully recovered. In summary, accidental exenatide overdosing was associated with short-term gastrointestinal sequelae and the possibility of an increased hypoglycemia risk. Adverse events due to overdosing have so far been managed successfully with prompt and appropriate medical care.

Hypoglycemia

In the MacConell et al. integrated analysis, the overall incidence of hypoglycemia was comparable between groups without SFU use, but between-group differences became apparent when hypoglycemic events were evaluated based on concomitant use of insulin-secretogogue SFU therapy [136]. The incidence rate of mild-to-moderate or major hypoglycemia without concomitant SFU therapy was 3.1% with exenatide and 2.7% with comparators. In contrast, hypoglycemia was more prevalent when exenatide was administered with a SFU (26.5%) than in the pooled comparator cohort (20.7%).

In individual phase 3 exenatide clinical trials major/severe hypoglycemia was rare with 10-mcg ExBID or 2-mg ExQW exposure (Table 3) [86-120]1,2, ranging from <1% to 4%. The incidence of all cases of reported hypoglycemia ranged from 0% to 58% upon initiation of 10-mcg ExBID (preceded by 4 weeks of 5-mcg ExBID) and 1% to 8% upon first initiation of 2 mg ExQW. Concomitant use of insulin-secretogogue SFU was more often associated with hypoglycemic events than was concomitant MET use. Insulin was usually, but not always, associated with more hypoglycemia than exenatide. In addition, nocturnal hypoglycemia was significantly more frequent in subjects treated with insulin glargine or aspart than with exenatide.

In summary, major/severe hypoglycemia has rarely been observed with ExBID or ExQW use. In the absence of concomitant SFU therapy, the risk of mild-to-moderate hypoglycemia is low. Concomitant SFU increases the risk of hypoglycemic events and SFU discontinuation should be considered when initiating exenatide. ExBID use is associated with a reduced incidence of nocturnal hypoglycemia compared with insulin.

Pancreatitis

In postmarketing data, exenatide administration has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Of note, acute pancreatitis has been observed in patients treated with exenatide, but it has not been shown that exenatide was causally associated with this adverse event, as will be discussed below. Patient characteristics associated with an increased risk of pancreatitis are overweight/obesity, alcohol use, smoking status, and prior pancreatitis/cholelithiasis/cholecystectomy [136]. In the MacConell et al. [137] integrated analysis discussed above, composite exposure-adjusted incidence rates per 100 patient-years for pancreatitis were not statistically different between the exenatide and pooled comparator groups (0.27 versus 0.18) (Fig. 13). In addition, occurrence of acute pancreatitis was rare, with a comparable incidence rate of 0.1% in each cohort. In individual phase 3 exenatide clinical trials, pancreatitis was also rare with ExBID or ExQW exposure (Table 3) [86-120]1,2.

In an analysis using insurance claims from a large U.S. commercial health database, patients with T2DM initiating ExBID were propensity-score-matched with a similar cohort initiating MET or SFU (glyburide) [140]. In this study, exenatide initiators were more likely to be overweight/obese with dyslipidemia and hypertension. Baseline prevalences of gallstone disease (0.8%) and alcohol dependence syndrome (0.1% to 0.2%) were low and comparable across matched-pairs. The estimated absolute risk of hospitalization associated with a primary diagnosis of acute pancreatitis was 0.13% among patients treated with exenatide compared with 0.13% for the matched MET/Gly cohort suggesting that there was no apparent difference in risk. One limitation of
### Table 3. Overview of Nausea, Vomiting, Hypoglycemia, and Selected Treatment-Emergent Adverse Events from Phase 3 Exenatide Clinical Trials

| Citation          | Treatment                  | Nausea (%) | Vomiting (%) | Hypo (%) | Major/Severe Hypo? | Other Relevant Observations |
|-------------------|----------------------------|------------|--------------|----------|-------------------|-----------------------------|
| **EXENATIDE BID CLINICAL TRIALS** |                           |            |              |           |                  |                             |
| Bergenstal 2009 [86] | ExBID+MET+SFU             | 29         | NG           | 29       | No                | 1.28 hypo/subj-y.           |
|                   | Aspart QD+MET+SFU         | 9          | NG           | 56       | 3.2%              | 4.02 hypo/subj-y. P=0.0013 vs Ex |
|                   | Aspart BID+MET+SFU        | 8          | NG           | 61       | 4.8%              | 5.25 hypo/subj-y. P<0.0001 vs Ex |
| Blonde 2006 [87]   | ExBID+MET +/- or SFU      | 14-29      | NG           | 7-12     | 0.7%              | The severe hypo event occurred in a patient treated with SFU |
| Bunck 2009 [88]    | ExBID+MET                | 50         | NG           | 8.3      | No                | 1 pancreatitis, resolved after Ex stopped |
|                   | Glarg+MET                 | NG         | NG           | 24.2     | No                |                             |
| Bunck 2011 [89]    | ExBID+MET                | 38.1       | 9.5          | 19.0     | No                |                             |
|                   | Glarg+MET                 | NG         | 8.0          | 28.0     | No                |                             |
| Buse 2011 [90]     | ExBID+Glarg              | 41         | 18           | 25.0     | No                | 1.4 hypo/subj-y. Nocturnal: 17% hypo |
|                   | PBO+Glarg                | 8          | 4            | 29.0     | 1%                | 1.2 hypo/subj-y. P=0.49 vs Ex Nocturnal: 26% hypo |
| Buse 2009 [91]     | ExBID+MET±SFU            | 28.0       | 9.9          | 34.5     | 0.9%              | 2.6 minor hypo/subj-y. Major hypo had SFU |
|                   | LIRA+MET±SFU             | 25.5       | 6.0          | 26.0     | No                | 1.9 minor hypo/subj-y. P=0.0131 vs Ex 1 mild pancreatitis |
| Buse 2004 [92]     | ExBID+MET +/- or SFU     | 51         | 13           | 36       | No                |                             |
|                   | 5 mcg ExBID+MET +/- or SFU | 39       | 10           | 14       | No                |                             |
|                   | PBO+MET +/- or SFU       | 7          | 2            | 3        | No                |                             |
| Buse 2007 [93]     | ExBID+MET +/- or SFU     | 8-39       | NG           | <1-13    | 0.2%              | 1 severe hypo in 1010 subj-y |
| Davies 2009 [94]   | ExBID+MET +/- or SFU +/- or TZD | 48.3    | NG           | 50.0     | 4.2%              | Nocturnal hypo: 11.9%. |
|                   | Glarg+MET +/- or SFU +/- or TZD | 2.6    | NG           | 59.6     | 5.3%              | Nocturnal hypo: 29.8%. P=0.001 vs Ex |
| DeFronzo 2005 [95] | ExBID+MET               | 45         | 12           | 5        | No                |                             |
|                   | 5 mcg ExBID+MET          | 36         | 11           | 5        | No                |                             |
|                   | PBO+MET                 | 23         | 4            | 5        | No                |                             |
| Derosa 2010 [96]   | ExBID+MET               | NG         | NG           | 0        | NG                |                             |
|                   | Glibenclamide+MET        | NG         | NG           | 4.6      | NG                |                             |
| Derosa 2011 [97]   | ExBID+MET               | NG         | NG           | 0        | NG                |                             |
|                   | Glibenclamide+MET        | NG         | NG           | 5.6      | NG                |                             |
| Forti 2008 [98]    | ExBID at B/D+MET±SFU±TZD | 22.6       | 10.0         | NG       | 4.2%              | 5.21 hypo/subj-y. P=0.393 vs Ex L/D |
|                   | ExBID at L/D+MET±SFU±TZD | 25.1       | 10.2         | NG       | 0.5%              | 6.51 hypo/subj-y.           |
| Gallwitz 2011 [99] | ExBID+MET               | 18.8       | 9.9          | 8.0      | No                | Nocturnal hypo: 3.9%        |
|                   | Aspart+MET               | NG         | NG           | 20.5     | No                | Nocturnal hypo: 7.0%        |
| Citation               | Treatment                        | Nausea (%) | Vomiting (%) | Hypo (%) | Major/Severe Hypo? | Other Relevant Observations |
|------------------------|----------------------------------|------------|--------------|----------|--------------------|-----------------------------|
| Gao 2009 [100]         | ExBID+MET±SFU                    | 25.5       | 15.8         | 35.5     | 0.9%               | 4.4 hypo/subj-y. MET only: 1.8 hypo/subj-y MET+SFU: 4.7 hypo/subj-y |
|                        | PBO+MET±SFU                      | 0.9        | 0            | 9.0      | 0.4%               | 0.5 hypo/subj-y MET only: 0.22 hypo/subj-y MET+SFU: 0.54 hypo/subj-y |
| Gill 2010 [101]        | ExBID+MET+/or TZD                | 36         | NG           | 7        | No                 |                             |
|                        | PBO+MET+/or TZD                  | 19         | NG           | 4        | No                 |                             |
| Heine 2005 [102]       | ExBID+MET+SFU                    | 57.1       | 17.4         | NG       | 1.4%               | 7.3 hypo/subj-y. Nocturnal hypo: 21%; 0.9 hypo/subj-y |
|                        | Glarg+MET+SFU                    | 8.6        | 3.7          | NG       | 1.5%               | 6.3 hypo/subj-y. Nocturnal hypo: 43%; 2.4 hypo/subj-y |
| Kadowaki 2009 [103]    | ExBID+SFU±MET, +SFU±TZD          | 35.1       | 8.1          | 54.1     | No                 |                             |
|                        | 5 mcg ExBID+SFU±MET, +SFU±TZD    | 8.1        | 13.5         | 43.2     | No                 |                             |
|                        | 2.5 mcg ExBID+SFU±MET, +SFU±TZD | 10.8       | 5.4          | 27.0     | No                 |                             |
|                        | PBO+SFU±MET, +SFU±TZD            | 0          | 0            | 10.0     | No                 |                             |
| Kadowaki 2011 [104]    | ExBID+SFU, +SFU+MET, +SFU+TZD    | 36.1       | 16.7         | 58.3     | No                 |                             |
|                        | 5 mcg ExBID+SFU, +SFU+MET, +SFU+TZD | 25.0       | 4.2          | 51.4     | No                 |                             |
|                        | PBO+ExBID+SFU, +SFU+MET, +SFU+TZD | 8.6        | 2.9          | 22.9     | No                 |                             |
| Kendall 2005 [105]     | ExBID+MET+SFU                    | 48.5       | 13.7         | 27.8     | No                 | Lower hypo incidence in SFU MIN group |
|                        | 5 mcg ExBID+MET+SFU              | 39.2       | 14.7         | 19.2     | 4.1%               |                             |
|                        | PBO+MET+SFU                      | 20.6       | 4.5          | 12.6     | No                 |                             |
| Klonoff 2008 [106]     | ExBID+MET+SFU                    | 59.0       | NG           | 40.0     | 0.2%               | All severe hypo events occurred in patients treated with SFU |
| Liukus 2010 [107]      | ExBID+TZD±MET                    | 12         | 8            | 4.0      | No                 |                             |
|                        | PBO+TZD±MET                      | 2          | 0            | 2.0      | No                 |                             |
| Moretto 2008 [108]     | ExBID                            | 13         | 4            | 4        | No                 | 0.52 hypo/subj-y            |
|                        | 5 mcg ExBID                      | 3          | 4            | 5        | No                 | 0.21 hypo/subj-y            |
|                        | PBO                              | 0          | 0            | 1        | No                 | 0.03 hypo/subj-y. P=0.014 vs Ex |
| Nauck 2007 [109]       | ExBID+MET+SFU                    | 33.2       | 15.0         | NG       | No                 | 4.7±0.7 hypo/subj-y. Nocturnal hypo: 17%. |
|                        | Aspart+MET+SFU                   | 0.4        | 3.2          | NG       | No                 | 5.6±0.7 hypo/subj-y. Nocturnal hypo: 25%; P<0.038 vs Ex |
Table 3. contd…

| Citation            | Treatment                  | Nausea (%) | Vomiting (%) | Hypo (%) | Major/Severe Hypo? | Other Relevant Observations                                                                 |
|---------------------|----------------------------|------------|--------------|----------|-------------------|------------------------------------------------------------------------------------------------|
| Ratner 2006 [110]   | ExBID+MET                  | 14-33      | 1-5          | NG       | No                |                                                                                               |
| Riddle 2006 [111]   | ExBID+SFU±MET              | 14-27      | NG           | 8-15     | 1.0%              |                                                                                               |
| Zinman 2007 [112]   | ExBID+TZD±MET              | 39.7       | 13.2         | 10.7     | No                |                                                                                               |
|                     | PBO+TZD±MET                | 15.2       | 0.9          | 7.1      | No                |                                                                                               |

**EXENATIDE QW CLINICAL TRIALS**

| Citation            | Treatment                  | Nausea (%) | Vomiting (%) | Hypo (%) | Major/Severe Hypo? | Other Relevant Observations                                                                 |
|---------------------|----------------------------|------------|--------------|----------|-------------------|------------------------------------------------------------------------------------------------|
| Bergenstal 2010 [113]| ExQW+MET                   | 24         | 11           | 1        | No                |                                                                                               |
|                     | SITA+MET                   | 10         | 2            | 3        | No                |                                                                                                |
|                     | PIO+MET                    | 5          | 3            | 1        | No                | 2 cases of pancreatitis                                                                          |
| Blevins 2011 [114]  | ExQW+D/E, MET, SFU, TZD or any combo | 14.0 | 4.7          | 3.9      | No                | All hypo events occurred in patients treated with SFU                                           |
|                     | ExBID+D/E, MET, SFU, TZD or any combo | 35.0 | 8.9          | 3.3      | No                | All hypo events occurred in patients treated with SFU                                           |
| Buse 2010 [115]     | ExQW+D/E, MET, SFU, TZD or 2 OADs | 7.0        | 6.3          | NG       | No                | All hypo events occurred in patients treated with SFU                                           |
|                     | ExBID then ExQW, +D/E, MET, SFU, TZD or 2 OADs | 7.7 | 4.6          | NG       | No                | All hypo events occurred in patients treated with SFU                                           |
| Buse 20111          | ExQW+MET, SFU, TZD or any comb | 9.3        | 3.7          | 10.8     | No                |                                                                                                |
|                     | LIRA+MET, SFU, TZD or any comb | 20.4       | 10.7         | 8.9      | No                |                                                                                                |
| Diamant 2010 [116]  | ExQW+MET±SFU               | 13         | 4            | 8        | No                | Hypo with MET: p<0.0001 vs Ex+MET                                                              |
|                     | Glarg+MET±SFU              | 1          | 1            | 26       | No                | Hypo with MET+SFU: p=0.0009 vs Ex+MET+SFU                                                      |
|                     |                            |            |              |          |                   | Nocturnal hypo                                                                                 |
|                     |                            |            |              |          |                   | Hypo with MET: p=0.028 vs Ex+MET                                                              |
|                     |                            |            |              |          |                   | Hypo with MET+SFU: p=0.0005 vs Ex+MET+SFU                                                      |
| Drucker 2008 [117]  | ExQW+D/E, MET, SFU, TZD or 2 OADs | 26.4 | 10.8         | 5.4      | No                | Hypo with SFU: 14.5% vs 0% without SFU                                                         |
|                     | ExBID then ExQW, +D/E, MET, SFU, TZD or 2 OADs | 34.5 | 18.6         | 6.1      | No                | Hypo with SFU: 15.4% hypo vs 1.1% without SFU                                                  |
| MacConell 20112     | ExQW+D/E, MET, SFU, TZD or 2 OADs | 16 (wks 30-156) | NG         | NG        | No                |                                                                                                |
Table 3. contd…

| Citation          | Treatment | Nausea (%) | Vomiting (%) | Hypo (%) | Major/Severe Hypo? | Other Relevant Observations |
|-------------------|-----------|------------|--------------|----------|-------------------|-----------------------------|
| Russell-Jones     | ExQW      | 11.3       | 4.8          | 5.2      | No                |                             |
| 2012 [118]        | MET       | 6.9        | 3.3          | 4.1      | No                |                             |
|                   | PIO       | 4.3        | 3.1          | 3.7      | No                |                             |
|                   | SITA      | 3.7        | 1.8          | 3.1      | No                |                             |
| Taylor 2011       | ExQW+D/E, MET, SFU, TZD or 2 OADs | 12* | 9* | 6.6* | No | **Wk 30-104 Hypo with SFU: 94% (16/17 subj) |
| [119]             |           |            |              |          |                   |                             |
| Wysham 2011       | ExQW+MET  | 5.0**      | 5.0**        | 1**      | No                | **Wk 26-52                  |
| [120]             | SITA then ExQW, +MET | 10.8** | 3.8** | 2** | No | **Wk 26-52 |
|                   | PIO then ExQW, +MET | 9.6** | 2.6** | 1** | No | **Wk 26-52 |

Note: when 'ExBID' is listed without dose, dose was 10 mcg BID. When ExQW listed without dose, dose was 2 mg.
Abbreviations: Aspart insulin aspart; B, breakfast; BID, twice daily; D, dinner; Ex, exenatide; GLARG, insulin glargine; Hypo, hypoglycemic events; hypo/subj-y, number of hypoglycemic events per subject year; L, lunch; MET, metformin; MIN, minimum; Lira, liraglutide; NG, not given; PBO, placebo; PIO, pioglitazone; QW, once weekly; Sita, sitagliptin; Subj, subject; SFU, sulfonylurea; TZD, thiazolidinedione; vs, versus; Wk, week; Y, year.

Fig. (13). Adverse events of interest. Exposure-adjusted incidence rate (EAIR) and risk difference of thyroid neoplasm, pancreatitis, renal impairment, and major adverse cardiac events (MACE). ExBID n=3261. Pooled comparator n=2333. MACE n=2316 and 1629, respectively. Thyroid neoplasm includes benign neoplasm of thyroid gland and malignant thyroid neoplasm. Pancreatitis includes acute pancreatitis and chronic pancreatitis. Renal impairment includes renal failure. MACE includes stroke, myocardial infarction, cardiac mortality, acute coronary syndrome, and revascularization procedures. 95% confidence interval for the risk difference (RD, ExBID incidence rate [%] minus pooled comparator incidence rate [%]). MACE analysis: risk ratio (RR) and 95% confidence interval for the RR. PY=patient-years. (Reprinted with permission from reference [137]).

Figures and tables are placeholders and need to be properly formatted in the final document. The text here is intended to provide a clear and accurate representation of the content for further processing.
more than 62 days after exhaustion of a patient’s drug supply, was associated with an increased risk (risk ratio 2.8). However, after adjustment for all chart-derived patient characteristics associated with an increased risk of pancreatitis (overweight/obese, alcohol use, smoking status, and prior pancreatitis/cholelithiasis/cholecystectomy) and contemporaneous claim-identified covariates, the past-time estimate was consistent with no increased risk for acute pancreatitis with past exenatide exposure relative to past exposure to other antidiabetes drugs (odds ratio 1.1).

Based on the medical literature (range 1950 to January 2010), FDA website (range 2005 to August 2008), and Amylin Pharmaceuticals database, Anderson and Trujillo [143] published a review of pancreatitis reports associated with ExBID use. The pancreatitis incident rate during clinical development was 1.8 per 1000 subject years for exenatide, compared with 2.6 per 1000 subject years for PBO and 0.9 per 1000 subject years for insulin. Among the FDA-reviewed post-marketing cases of pancreatitis, all 6 patients with hemorrhagic or necrotizing pancreatitis required hospitalization and 2 died. For the 30 other cases of pancreatitis, 19 patients were female (63%) with a median age of 60 years and a time-to-onset of symptoms ranging from 4 to 300 days after exenatide initiation (median 34 days post-exenatide). In 22 cases of pancreatitis the patients improved after exenatide discontinuation and in 21 cases of pancreatitis the patients required hospitalization. Of note, 27 of the 30 patients had at least one other risk factor for acute pancreatitis.

Elashoff et al. [144] used the U.S. Food and Drug Administration (FDA) adverse event reporting system (AERS) database to analyze putative associations between exenatide and cases of pancreatitis, pancreatic cancer, thyroid tumors, and all cancers. As cautioned by the authors, the FDA AERS database depends on spontaneous reporting and is thus, subject to reporting biases. The control antidiabetes drugs were rosiglitazone (TZD), nateglinide, repaglinide, and glipizide (SFU). Back pain, urinary tract infection, chest pain, cough, and syncope were prospectively defined as the control adverse events. By design, no comparable analyses were performed to assess the rates of pancreatitis and cancer associated with the control drugs. The fundamental assumptions in the analysis were no association between the control drugs and control events, or between exenatide and control events. The period covered was 2004 through the third quarter of 2009. Within this framework, the authors found an increased risk of pancreatitis and pancreatic cancer associated with exenatide compared with the control drugs (odds ratio 10.68). When the subset of pancreatitis reports in 2006 and prior (before the first cautionary letter from the FDA in 2007) were analyzed, the odds ratio for exenatide, compared with control drugs, was 2.57 for pancreatitis, 2.95 for pancreatic cancer, 4.73 for thyroid cancer, and 1.08 for all other cancers. Given the potentially serious safety concerns raised by Elashoff et al. [144], the European Association for the Study of Diabetes (EASD) evaluated the report in detail [145]. The EASD acknowledged the importance of continual safety monitoring of diabetes therapeutics, but concluded there was no definitive evidence pointing to an increased cancer risk with incretin-based medications. The EASD reiterated the incompleteness and bias associated with spontaneous adverse events reporting systems such as the FDA database. Also, given the analysis period covered by Elashoff et al. [144], there was a significant amount of time before exenatide market introduction when only events with control therapy were collected, possibly introducing further bias. In addition, reported events are not evaluated for their adherence to accepted diagnostic standards. EASD stated that the only robust way of measuring comparative risk is within randomized control trials.

In summary, the incidence of acute pancreatitis is rare in patients with T2DM, whether or not they are being treated with exenatide or other diabetes drugs. However, additional monitoring to compile long-term exposure data is warranted, with randomized, controlled clinical trials as the recommended methodology.

All patients treated with exenatide should be monitored for the signs and symptoms of pancreatitis, including persistent severe abdominal pain, possibly radiating to the back, which may or may not be accompanied by vomiting [135,146]. If pancreatitis is suspected, exenatide should be discontinued. If pancreatitis is confirmed, exenatide should not be restarted. Exenatide should not be used in patients with a history of pancreatitis.

Neoplasias

In both genders of rats, exenatide caused a dose-related and treatment-duration dependent increase in the incidence of thyroid C-cell tumors at clinically relevant exposures compared to controls [136,146]. A significant increase in malignant thyroid C-cell carcinomas was observed in female rats receiving exenatide at 25-times clinical exposure compared to controls and higher incidences were noted in males above controls in all treated groups at ≥2-times clinical exposure. Other GLP-1 receptor agonists have also been shown to induce thyroid C-cell adenomas and carcinomas in male and female mice and rats at clinically relevant exposures [144]. It is unknown whether exenatide will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide-induced rodent thyroid C-cell tumors could not be determined by clinical or nonclinical studies.

As to the topic of ‘thyroid cancer’ in humans raised by the Elashoff et al. analysis [144], the EASD [145] stated that there are different categories of thyroid cancer, with different molecular characteristics and etiologies. The only form possibly mechanistically-related to incretin-based antidiabetic drugs that could potentially be influenced by therapies leading to enhanced stimulation of the GLP-1R is a cascade leading from C-cell hyperplasia to C-cell adenoma to medullary thyroid carcinoma. Medullary thyroid carcinoma is one of the rarer forms of thyroid tumors and it seems counter-intuitive that a change in the incidence in medullary thyroid carcinoma would change the overall incidence of thyroid carcinomas. A similar viewpoint was expressed by Spranger et al. [147] for the Drug Commission of the German Medical Association. According to the authors, the time between tumor induction, tumor development, and metastasis/clinical diagnosis generally extends more than 10 years. By contrast, spontaneous adverse drug reactions in the German national database consistently found the time between initial exenatide exposure and tumor detection to be much shorter (2
to 33 months). Thus, the authors concluded that a role for exenatide in tumor induction was doubtful.

In the MacConell et al. integrated analysis [137], a small difference was observed between the exenatide BID and pooled comparator groups in the incidence of thyroid tumors (0.3% versus 0.0%, respectively).

In summary, a causal relationship between the development of neoplasias and treatment with exenatide or other diabetes drugs has not been proven in patients with T2DM. However, additional monitoring to compile long-term exposure data is warranted, with randomized, controlled clinical trials as the recommended methodology. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not be treated with exenatide [136,146].

**Exenatide Use in Renal Disease**

Exenatide is primarily metabolized and cleared in the kidney [148], and exenatide pharmacokinetics are significantly altered (i.e., reduced clearance rate, increased half-life) in nondiabetic adults with end-stage renal disease [149]. In addition, ExBID may induce nausea and vomiting, resulting in transient hypovolemia possibly leading to worsened renal function. Therefore, it is prudent to proceed conservatively in patients with moderate renal impairment (creatinine clearance <30 mL/min) and to avoid exenatide use completely in patients with end-stage renal disease or severe renal impairment (creatinine clearance <30 mL/min) [136,146].

In the MacConell et al. [137] integrated ExBID analysis, there was no between-cohort difference in exposure-adjusted incidence rates per 100 patient-years for renal impairment/failure (1.6 for each cohort).

In summary, caution should be used when initiating or escalating exenatide therapy in patients with T2DM and moderate renal impairment. Exenatide should not be used in patients with end-stage renal disease or severe renal impairment (creatinine clearance <30 mL/min), and should be used with caution in patients with renal transplantation.

**Cardiovascular Effects**

Ratner et al. [150] reported a retrospective analysis of major adverse cardiac events (MACE) in 3945 subjects from 12 randomized exenatide BID clinical trials; 8 PBO-controlled and 4 active comparator-controlled (Fig. 14). For this evaluation, MACE included cardiovascular mortality, stroke, myocardial infarction, acute coronary syndrome, and revascularization procedures. Of note, in the clinical trials included in this analysis, patients were excluded from study participation if they had a significant history of cardiac disease at screening, or active cardiac disease within 1 year prior to screening. In this population, MACE occurred infrequently. At baseline, mean HbA1c was 8.3% to 8.4%, mean BMI was 31.3 to 31.5 kg/m², mean systolic BP was 131 to 132 mmHg, and mean diastolic BP was 79 mmHg. There were 4 fatal CV events, 2 in each treatment cohort. The exenatide cohort had an exposure-adjusted incidence rate per 100 patient-years of 1.9, versus 2.5 for the comparator cohort. In a weighted Kaplan-Meier plot a significantly higher percentage of the exenatide cohort than the pooled comparator cohort were free of a primary MACE event over 1 year.

The effects of 10-mcg ExBID on heart rate was prospectively evaluated in a small, 12-week, PBO-controlled pilot study [101]. Overweight patients with T2DM with stage-1 hypertension and treated with MET, TZD, or MET+TZD for their hyperglycemia had no change from baseline in heart rate in either treatment arm. Exenatide was not associated with a significant change from baseline in mean 24-hour, daytime, or nighttime heart rate within or between groups.

Overall, available clinical trial data indicate that treatment with exenatide BID does not increase cardiovascular risk in patients with T2DM.

**Anti-exenatide Antibody Formation and Injection-site Reactions**

Xenogenic peptide therapies, such as exenatide, often stimulate an antibody response and the clinical impact of this immune response can range from none to life threatening [151]. Antibody rates for all xenogenic peptide therapies can vary from less than 1% to over 70%. However, not all antibodies are neutralizing, nor do all antibody responses result in attenuation of drug efficacy, altered pharmacokinetics/pharmacodynamics, or changes in drug clearance. In the majority of cases, the antibody response to xenogenic peptides is benign, with minimal clinical impact.

In an integrated analysis of patients with T2DM exposed to ExBID in controlled clinical trials, 35% of all patients were antibody-positive at endpoint (12 to 52 weeks of treatment); 33% of all patients had low antibody titers (≤125) [152]. For patients exposed to ExQW in clinical trials, 57% were antibody-positive at the endpoints of the controlled periods (24 to 30 weeks); but most (88%) had low antibody titers. In ExQW patients, 22% with detectable antibodies had potentially immune-related treatment-related adverse events, versus 12% in antibody-negative subjects and 10% in the pooled comparator control group. Injection-site erythema or pruritus was reported in 13.6% of antibody-negative patients treated with ExQW, compared with 3.1% of antibody-negative patients and 2.9% of comparator control patients. No anaphylactic reactions occurred with either exenatide formulation.

In summary, anti-exenatide antibody responses are common in patients treated with ExBID or ExQW. However, the incidence of all immune-related adverse events is low. Injection-site erythema or pruritus was observed in patients treated with ExQW, but no anaphylactic reactions have occurred with either exenatide formulation.

**Special Populations**

One small PBO-controlled study directly compared exenatide safety in elderly patients with T2DM ≥75 years of age (n=15) with middle-aged patients with T2DM ≥45 to ≤65 years of age (n=15) [153]. At baseline, the elderly cohort had mild or moderate renal impairment, while the middle-aged cohort had normal renal function. Treatment was administered over three consecutive days. Nausea and vomiting with ExBID were more prevalent in the elderly cohort (nausea: 6 patients versus control 3 patients; vomiting: 3
patients versus 1 control patient). All other adverse events were similar in both groups, and none were severe in intensity. There were no reports of hypoglycemia.

**FUTURE DIRECTIONS**

A once monthly formulation of exenatide (ExQM) is currently undergoing clinical evaluation. This formulation uses the extended-release microspheres of ExQW with a triglyceride-based diluent to enable delivery of higher exenatide doses less frequently. A 20-week, randomized, open-label, controlled trial was conducted in 121 patients with T2DM treated with diet/exercise, MET, TZD (pioglitazone) or MET+TZD. Three ExQM doses (5, 8, or 11 mg) administered 5 times as directed were compared with ExQW administered 20 times. Sustained plasma exenatide concentrations were achieved with all ExQM doses, although greater peak-to-trough variability in exenatide pharmacokinetic profiles was observed with ExQM than with ExQW. However, the mean trough concentrations remained within the therapeutic range with all ExQM doses. The 8- and 11-mg ExQM doses achieved plasma exenatide concentrations similar to those of ExQW. All three ExQM doses reduced mean HbA1c by -1.3% to -1.5%, compared with an ExQW mean HbA1c reduction of -1.5%. Seventy percent of patients achieved an HbA1c<7% on the 11-mg ExQM dose versus 48% with ExQW. Patients dosed with 11-mg ExQM lost -1.1 kg of body weight, compared with -1.4 kg in the ExQW group.

---

*MacConell L, Malloy J, Huang W, Cirincione B, Shen L, Porter L. Safety and efficacy of once-monthly exenatide over 20 weeks in patients with type 2 diabetes. Annual meeting of the American Diabetes Association, June 2011. Late-breaking abstract 46-LB accessed at http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=82452.*

---

![Fig. (14). (A) Relative risk of primary MACE and secondary cardiovascular endpoints with ExBID relative to pooled comparators. (B) Weighted Kaplan-Meier plot for patients without a primary MACE event by treatment in controlled ExBID studies. (Reprinted with permission from reference [150]).](image)
The overall safety profile was comparable between ExQM and ExQW. No hypoglycemia was observed. Based on these preliminary results, more extensive clinical trials are planned.

An ongoing, prospective morbidity and mortality outcomes study (EXSCEL) is expected to further elucidate the potential cardiovascular implications of ExQW in patients with T2DM. The primary outcome measure is the time to first cardiovascular event in a combined endpoint consisting of cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke. Secondary endpoints include the time to all-cause mortality, time to first cardiovascular event, time to hospitalization for acute coronary syndrome, and time to hospitalization for heart failure. Recruitment for this trial is ongoing.

SUMMARY AND CONCLUSION

This review presents an overview of the evolution of exenatide as a treatment for T2DM beginning with the realization of the importance of the ‘incretin effect’, through seminal preclinical discoveries, clinical pharmacology investigations, and phase 3 clinical trials. Currently, a twice daily exenatide formulation is approved for use in patients with T2DM in the U.S., E.U., Japan, and other countries. More recently, a once weekly exenatide formulation was approved for use in the U.S. and EU. In addition, a once-monthly exenatide formulation is undergoing clinical testing. In patients with T2DM, glycemic control is not always achieved, and some therapeutic interventions cause hypoglycemia and weight gain, or possibly exacerbate the risk of CVD. In clinical trials, exenatide treatment has addressed these unmet medical needs with T2DM patients experiencing improved glycemia, weight loss, and a low frequency of hypoglycemia in the absence of concurrent SFU (insulin secretagogue) use. The effects of exenatide have been shown to be mediated through enhanced glucose-dependent insulin secretion, suppressed inappropriate elevated glucagon secretion, slowed gastric emptying, and enhanced satiety.

In controlled phase 3 clinical trials ranging from 12 to 52 weeks in duration, 10-mcg ExBID reduced mean HbA1c by -0.8% to -1.7%, accompanied by mean weight loss ranging from -1.2 kg to -8.0 kg, plus improvements in a broad range of cardiometabolic risk factors. Efficacy has been demonstrated as monotherapy and in various combinations with metformin (MET), sulfonylureas (SFU), thiazolidinediones (TZD), and insulins. During phase 3 clinical evaluation of a once weekly exenatide (ExQW) formulation in patients with T2DM in controlled trials ranging from 24 to 30 weeks, 2 mg ExQW reduced mean HbA1c by -1.3% to -1.9%, accompanied by mean body weight reductions ranging from -2.3 to -3.7 kg; with 70% to 79% having reductions in both HbA1c and weight. In the DURATION-1 study extension, ExQW was associated with mean HbA1c reductions of -2.0% at Year 1 and -1.7% at Year 2, on a background of diet/exercise, MET, SFU, TZD, or 2 oral antidiabetes drugs; the corresponding mean weight reductions were -4.1 kg and -2.6 kg.

The most common side effects are gastrointestinal in nature, mild, and transient. Nausea is the most prevalent adverse event and tends to decrease in frequency with continued exenatide exposure. The incidence of hypoglycemia without concomitant SFU therapy is generally low; hypoglycemia incidence increases when exenatide is used in conjunction with a SFU. Rare cases of pancreatitis have been reported, typically at the same incidence rate as for other diabetes drugs. A causal relationship between the development of neoplasias and treatment with exenatide or other diabetes drugs has not been proven in patients with T2DM. However, additional monitoring to compile long-term exposure data is warranted, with randomized, controlled clinical trials as the recommended methodology. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not be treated with exenatide. No detrimental cardiovascular effects have been identified. Most patients develop low titer anti-exenatice antibodies with little or no physiological consequences. No anaphylaxis has been reported with exenatide use. Thus, by building upon early observations of anti-hyperglycemic actions of GLP-1 and Gila monster exendin-4, exenatide (synthetic exendin-4) has been successfully developed into a first-in-class diabetes therapeutic.

CONFLICT OF INTEREST

The author(s) confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENTS

The authors thank Dr. Loretta L. Nielsen for medical writing.

ABBREVIATIONS

| AERS   | adverse event reporting system |
| ALT    | alanine aminotransferase       |
| ApoB   | apolipoprotein B               |
| ASPART | biphasic insulin aspart 70/30 mix |
| AST    | aspartate aminotransferase     |
| B      | breakfast                      |
| BG     | background                     |
| BID    | twice daily                    |
| BL     | baseline                       |
| BP     | blood pressure                 |
| BIM    | body mass index               |
| Comb   | combination                    |
| CV     | cardiovascular                 |
| CVD    | cardiovascular disease         |
| D      | dinner                         |
| D/E    | diet and exercise              |
| DO     | study dropout rate             |
| DPP-4  | dipeptidyl peptidase-IV        |

5 Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. NCT01144338. Accessed May 14, 2012 at http://clinicaltrials.gov/ct2/show/NCT01144338.
Digest = duration of clinical trial
DURATION = Diabetes therapy Utilization Researching changes in HbA1c, weight and other factors Through Intervention with exenatide ONce weekly
EAIR = Exposure-adjusted incidence rate
Ex = exenatide
GLP-1 = glucagon-like peptide-1
EASD = European Association for the Study of Diabetes
F = female
FDA = U.S. Food and Drug Administration
GIP = glucose-dependent insulinotrophic polypeptide/ gastric inhibitory polypeptide
Geo = geometric
GLARG = insulin glargine
HDL-C = high density lipoprotein cholesterol
Gli = glibenclamide sulfonylurea
HbA1c = glycated hemoglobin
HOMA = homeostasis model assessment
hsCRP = high sensitivity C-reactive protein
Hypo = hypoglycemic events
ILM = intensive lifestyle modification
KO = knockout
L = lunch
LDL-C = low density lipoprotein cholesterol
LIRA = liraglutide
LS = least squares
MACE = major adverse cardiac events
MET = metformin
MIN = minimum
NA = not applicable
NG = not given
NI = non-inferiority
OAD = oral antidiabetes drug
PBO = placebo
PIO = pioglitazone
Pop = population
PTH = parathyroid hormone
QD = once daily
QM = once monthly
QW = once weekly
oxLDL = oxidated low density lipoprotein
ROSI = rosiglitazone
ΔRx = change or different diabetes medication prior to randomization
S = superiority
SFU = sulfonylurea
Sita = sitagliptin
Subj = subject
T2DM = type 2 diabetes mellitus
T50 = time to achieve 50% stomach emptying
TID = thrice daily
Tmax = time to reach maximal blood concentration
TSH = thyroid stimulatory hormone
TZD = thiazolidinediones (TZD)
VLDL-C = very low density lipoprotein cholesterol
VS = versus
Wk = week
Wt = weight
Y = year

Clinical Trial Registration Numbers: See Table 1

REFERENCES
[1] World Health Organization diabetes facts and figures. Accessed August 27, 2011 at: http://www.who.int/diabetes/facts/en/.
[2] Centers for Disease Control and Prevention. Diabetes Data and Trends 2011; Diabetes Fact Sheet 2011. Accessed Feb. 11, 2012 at http://apps.nccd.cdc.gov/DDTSTRS/NationalSurvData.aspx.
[3] American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35: S11-S63.
[4] UK Prospective Diabetes Study Group: Overview of 6 years’ therapy of type II diabetes: A progressive disease. Diabetes 1995; 44: 1249-58.
[5] UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
[6] Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-83.
[7] Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-82.
[8] Nauck MA, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
[9] Dupré J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-8.
[10] Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
[11] Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-23.
[12] Raufman JP, Singh L, Singh G, Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from...
guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 1992; 267: 21432-7.

[13] Thorens B. Expression cloning of the pancreatic β-cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-5.

[14] Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinol 1994; 134: 2156-64.

[15] Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinol 1996; 137: 2968-78.

[16] Ban K, Noyan-Ashraf MH, Hoef er J, Bolz S, Drucker DJ, H usain M. Cardioprotective and vasodilatory actions of glucagon-like peptide-1 receptor are mediated through both glucagon-like peptide-1 receptor and independent pathways. Circulation 2008; 117: 2340-50.

[17] Scrocchi LA, Brown TJ, MacLusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 1996; 2: 1254-8.

[18] Flam ez D, Van Breusegem A, Scrocchi LA, et al. Mouse pancreatic β-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes 1998; 47: 646-52.

[19] Pederson RA, Satkunarajah M, McIntosh CH, et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide-1 receptor -/- mice. Diab etes 1998; 47: 1046-52.

[20] Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 1998; 47: 632-9.

[21] Scrocchi LA, Drucker DJ. Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. Endocrinol 1998; 139: 3127-32.

[22] Flam ez D, Gilson P, Moens K, et al. Altered CaAMP and Ca2+ signaling in pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 1999; 48: 1970-86.

[23] Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the heptoptral vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001; 50: 1720-8.

[24] De Leon DD, Deng S, Madani R, Ahima R, Drucker DJ, Stoffers DA. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 2003; 52: 365-71.

[25] Holst JJ, Enterooglucagon. Annu Rev Physiol 1997; 59: 257-71.

[26] Toft-Nielsen M, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137-43.

[27] Nauck MA, Niedererichholz U, Ettler R, et al. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Amer J Physiol 1997; 273: E981-8.

[28] Nauck MA, Wollschlager, Werner I, et al. Effects of subcutaneous glucagon-like peptide-1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-53.

[29] Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and depresses energy intake in humans. J Clin Invest 1998; 101: 515-20.

[30] Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obesity 2001; 25: 781-792.

[31] Näslund E, Bogefors J, Skogar S, et al. Exendin-4. J Biol Chem 1997; 272: 4108-15.

[32] Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide as an antagonist at the glucagon-like peptide 1 (1-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 1993; 268: 19650-55.

[33] Thorens B, Porrett A, Bühler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Diabetes 1993; 42: 1678-82.

[34] Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999; 42: 45-50.

[35] Young AA. Glucagon-like peptide-1, exendin and insulin sensitivity. In: Hansen B, Shahir E, Eds. Insulin Resistance and Insulin Resistance Syndrome. Harwood Academic, New York 2002; pp. 235-262.

[36] Eng J, Kleinnan WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem 1992; 267: 7402-5.

[37] Chen Y, Kissova I, Tzahar E, et al. Characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J Biol Chem 1997; 272: 4108-15.

[38] Green AE, Topple JR, EnG J, Goke B, Göke R. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide as an antagonist at the glucagon-like peptide 1 (1-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 1993; 268: 19650-55.

[39] Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026-34.

[40] Szany M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, Egan JM. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinol 2000; 141: 1936-41.

[41] Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG, Young AA. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332-40.

[42] Parkes DG, Pritter R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50: 583-9.

[43] Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabe tes 1999; 48: 2276-80.

[44] Tourrel C, Baille D, Meile MJ, Kergato M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50: 1562-70.

[45] Tourrel C, Baille D, Lacorne M, Meile MJ, Kergato M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51: 1443-52.

[46] Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinol 2005; 146: 2069-76.
Exenatide for Diabetes

Current Diabetes Reviews, 2013, Vol. 9, No. 2 191

[54] Stoffers DA, Desai BM, DeLeon DD, Simmons RA. Neonatal exendin-4 prevents the development of diabetes in the intraterine growth retarded rat. Diabetes 2003; 52: 734-40.

[55] Rolin B, Larsen MO, Gottfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-52.

[56] Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002; 45: 1263-73.

[57] Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, Young A. Pharmacokinetische actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53: 260-70.

[58] DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.

[59] Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.

[60] Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-7.

[61] Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-9.

[62] Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Amer J Health-Sys Pharm 2005; 62: 173-81.

[63] Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7: 467-77.

[64] Kothare PA, Linnebjerg H, Isaka Y, et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 2008; 48: 1389-99.

[65] Zhao X, Cui YM, Zhou Y, et al. Exenatide pharmacokinetics in healthy Chinese subjects. Int J Clin Pharmacol Ther 2008; 46: 459-65.

[66] Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411-7.

[67] Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-81.

[68] Green GM, Guan D, Schwartz IG, Phillips WT. Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: role in postprandial hyperglycaemia. Diabetologia 1997; 40: 136-42.

[69] DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH. One-year treatment with exenatide improves A1C, weight and cardiovascular effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-47.

[70] Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-hour glucose, glucoregulatory, and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011; 13: 982-9.

[71] Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab 2011; 96: 1763-70.

[72] Cervera A, Wajcberg E, Sreevijitakom A, Fernandez M, Zuo P, Triplitt C, Muriel D, DeFronzo RA, Cersosimo E. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008; 294: E846-52.

[73] Preumont V, Hermans MP, Brichard S, Buysschaert M. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab 2010; 36: 293-8.

[74] DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010; 33: 951-7.

[75] Egan JM, Cloquet AR, Elahi D. The insulinotropic effect of acute exenatide-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-90.

[76] Degn KB, Brock B, Juhl CB, Djehuus CB, Jaime Grubert J, Kim DL, Ram J, Tan Y, Shad S. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-403.

[77] Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010; 212: 217-22.

[78] Joslin Diabetes Center. Effect of exenatide plus rosiglitazone on beta-cell function and inflammatory stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011; 13: 143-8.

[79] Sathyaranayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity 2011; 19: 2310-5.

[80] Bergenstal R, Lewin A, Bailey T, Chang D, Gyltyn T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a basal insulin sulfonylurea. Curr Med Res Opin 2009; 25: 65-75.

[81] Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-47.

[82] Bunck MC, Diament M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen M, Smith U, Yki-Järvinen H, Heine RJ. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-8.

[83] Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Diament M, Deng W, Kendall DM, Taskinen M, Smith U, Yki-Järvinen H, Heine RJ. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors first- and second-phase insulin secretion in response to intra-venous glucose in subjects with type 2 diabetes. Current Diabetes Reviews 2011; 9: 591-7.

[84] Triplitt C, Muriel D, DeFronzo RA, Cersosimo E. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008; 294: E846-52.
Moretto TJ, Milton DR, Ridge TD, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139-53.

Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEEIA) study. Diabetes Obes Metab 2009; 11: 1153-62.

DeFrancesco RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycerol control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100.

Deroza G, Maffioli P, Salvedo SA, et al. Exenatide versus glimeclamide in patients with diabetes. Diabetes Technol Ther 2010; 12: 233-40.

Deroza G, Putignano P, Bossi AC, Bonaventura A, Querci F, Frangiotti IG, Guazzini B, Testori G, Fogari E, Maffioli P. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011; 666: 251-6.

Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira JH. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 2437-47.

Gallwitz B, Böhm M, Seget T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: A randomized 26-week study on glycerol control and hypoglycemia. Diabetes Care 2011; 34: 604-6.

Gao Y, Yoon KH, Chuang L, et al. Effects of exenatide monotherapy over 24 weeks in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Care 2004; 27: 309-17.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005; 143: 559-69.

Kadowaki T, Namba M, Yamanura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-24.

Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomised, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Invest 2011; 2: 210-7.

Kendall DM, Riddle MC, et al. Effects of exenatide (exendin-4) on glyceric control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91.

Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least three years. Curr Med Res Opin 2008; 24: 275-86.

Liu-Ltuk J, Rosas Guzman J, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab 2010; 12: 1065-68.

Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-60.

Nauk MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Truttmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 2007; 50: 259-67.

Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glyceric control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8: 419-28.

Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylurines or with or without metformin. Diab Metab Res Rev 2006; 22: 483-91.

Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Annals Int Med 2007; 146: 477-85.

Bergenstal RM, Wysym C, MacConell L, et al. for the DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 433-41.

Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L. DURATION-5: Exenatide once weekly resulted in greater improvements in glyceric control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-10.

Blevins T, Drucker DJ, Porter L, for the DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255-61.

Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): a placebo-label randomised trial. Lancet 2010; 375: 2343-43.

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L. For the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-50.

Russell-Jones D, Cuddihy RM, Hanelfeld M, et al. on behalf of the DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitaglitazone used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care 2012; 35: 252-8.

Taylor K, Gurney K, Han J, Pence R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glyceric control and weight loss over 2 years. BMC Endo 2011; 11: 9.

Wysym C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diab Med 2011; 28: 705-14.

Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123: 468.e9-17.

Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29: 2137-9.

DeFrancesco RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c, and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010; 27: 309-17.

Pence R, Brunell SC, Yan L, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocrin Pract 2012; 18: 227-37.

Purnell JW, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003; 2: 33-47.

Nelson P, Poon T, Gnan D, Schabbel CA, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diab Tech Ther 2007; 9: 317-26.
Exenatide for Diabetes

[128] Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S. Exenatide non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 2010; 122: 118-28.

[129] Okerson, T., Yan, P., Stonehouse, A., Brodows, R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Amer. J. Hyperten. 2010; 23: 334-9.

[130] Bunck MC, Cornér A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010; 212: 223-9.

[131] Bunck MC, Diamant M, Eliasson B, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010; 33: 1734-7.

[132] Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res 2005; 37: 627-32.

[133] DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D,L-1 actide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13: 1145-54.

[134] Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-93.

[135] Stonehouse A, Walsh B, Cuddihy R. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. Diabetes Technol Ther 2011; 13: 1063-9.

[136] BYDUREON (exenatide extended-release for injectable suspension) prescribing information. Revised January 2012. Accessed Feb. 16, 2012 at http://www.bydureon.com.

[137] MacConell L, Brown C, Gurney K, Han J. Safety and tolerability of exenatide BID in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo- and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012; 5: 29-41.

[138] Calara F, Taylor K, Han J, et al. A randomized, open-label, crossover study examining the effect of injection site bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005; 27: 210-5.

[139] Cohen V, Teperikidis E, Jellinek SP, Rose J. Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia. Clin Toxicol 2008; 46: 346-7.

[140] Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared with metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-27.

[141] Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-54.

[142] Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13: 559-560.

[143] Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonists. Ann Pharmacother 2010; 44: 904-9.

[144] Elshoff M, Matveyenko AV, Gier B, Elshoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterol 2011; 141: 150-6.

[145] European Association for the Study of Diabetes. EASD commentary on the publication by Elashoff et al. published online in Gastroenterology, February 2011: Increased incidence of pancreatitis and cancer among patients given glucagon-like peptide-1-based therapy. Accessed August 25, 2011 at: http://www.easd.org/easdwebfiles/statements/Elashoff_Commentary.pdf

[146] BYETTA (exenatide) injection prescribing information. Revised December 2011. Accessed Feb. 16, 2012 at http://www.byetta.com.

[147] Spranger J, Gundert-Remy U, Stammshulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterol 2011; 141: 20-23.

[148] Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006; 7: 367-74.

[149] Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317-27.

[150] Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf B, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diab 2011; 10: 22.

[151] Schnabel CA, Fineberg SE, Kim DD. Immunogenicity of xenopeptide hormone therapies. Peptides 2006; 27: 1902-10.

[152] Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy, and cross-reactivity with long-term treatment. Diab Obes Metab 2012. doi:10.1111/j.1463-1326.2012.01561.x

[153] Linnebjerg H, Kothare PA, Seger M, Wolk AM, Mitchell MI. Exenatide pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with type 2 diabetes. Int J Clin Pharmacol Ther 2011; 49: 99-108.

[154] Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.

[155] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterol 2007; 132: 2131-57.